CN101277934A - Metabotropic glutamate-receptor-potentiating isoindolones - Google Patents
Metabotropic glutamate-receptor-potentiating isoindolones Download PDFInfo
- Publication number
- CN101277934A CN101277934A CNA2006800363117A CN200680036311A CN101277934A CN 101277934 A CN101277934 A CN 101277934A CN A2006800363117 A CNA2006800363117 A CN A2006800363117A CN 200680036311 A CN200680036311 A CN 200680036311A CN 101277934 A CN101277934 A CN 101277934A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- cycloalkyl
- alkylaryl
- haloalkyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Anesthesiology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
The invention provides compounds of formula (I), wherein R<1> is a ring , and uses of the compounds in therapy as metabotropic glutamate receptors modulators, particularly in neurological and psychiatric disorders.
Description
The cross reference of related application
The right of priority that the P.C.T. that the application requires on August 12nd, 2005 to submit to applies for PCT/US2005/028760.
Background of invention
The application relates to performance as new compound, its preparation method of the function of glutamate receptor potentiators, the medicinal compositions that contains them and the purposes in treatment thereof.
Metabotropic glutamate receptor (mGluR) belongs to GTP-conjugated protein (G-albumen) coupled receptor family, and it is activated by L-glutamic acid, and plays an important role in the cynapse activity aspect central nervous system, neural plasticity, neurodevelopment and neurodegeneration.
The activation of mGluR in intact mammalian nervous unit produces one or more following responses: the activation of Phospholipase C; The increase of phosphoinositide (PI) hydrolysis; Intracellular Ca2+ discharges; The activation of phosphatidase D; The activation of adenylate cyclase and inhibition; Increase or minimizing that 3'5'-AMP (cAMP) forms; The activation of guanylyl (guanylyl) cyclase; The increase that cyclic guanosine monophosphate one phosphoric acid (cGMP) forms; Phosphide enzyme A
2Activation; The increase that arachidonic acid discharges; And voltage-and the active of part-gated ion channel increase or reduce (Schoepp etc., 1993, Trends Pharmacol.Sci., 14:13; Schoepp, 1994, Neurochem.Int., 24:439; Pin etc., 1995, Neuropharmacology 34:1; Bordi ﹠amp; Ugolini, 1999, Prog.Neurobiol.59:55).
8 kinds of mGluR hypotypes have been identified.Connect and the pharmacology collection of illustrative plates according to original series similarity, information conduction, these hypotypes are divided into three groups.The I group comprises mGluR1 and mGluR5, and it activates the generation of Phospholipase C and intracellular calcium signal.II group (mGluR2 and mGluR3) and III group (mGluR4, mGluR6, mGluR7 and mGluR8) mGluRs regulate the restraining effect of adenylyl cyclase activity and ring AMP level.Be to look back, referring to Pin etc., 1999, Eur.J.Pharmacol., 375:277-294.
The activity of mGluR family receptors relates to a large amount of normal processes among the Mammals CNS and is the important target of the compound of multiple neurological of treatment and psychiatric disorders.Need to activate that mGluR strengthens with the long time-histories of inducing hippocampus and the long time-histories of cerebellum fails (Bashir etc., 1993, Nature, 363:347; Bortolotto etc., 1994, Nature, 368:740; Aiba etc., 1994, Cell, 79:365; Aiba etc., 1994, Cell, 79:377).Proved the effect of mGluR activated (Meller etc., 1993, Neuroreport, 4:879 in injury sensation and the analgesia; Bordi ﹠amp; Ugolini, 1999, Brain Res., 871:223).In addition, thought that mGluR activates in various other normal processes, comprise in the control of maincenter control, awakening, behavior control and vestibulo-ocular reflex of cynapse conduction, neuronal development, apoptotic neuronal death, synaptic plasticity, space learning, scent-memorizing, cardiomotility, play regulating effect (Nakanishi, 1994, Neuron, 13:1031; Pin etc., 1995, Neuropharmacology is on seeing; Knopfel etc., 1995, J.Med.Chem., 38:1417).
Nearest progress aspect the neurophysiology effect of illustrating mGluR determined, these acceptors are as drug targets likely aspect and chronic neuropathic and psychiatric disorders and chronic and the acute pain disease acute in treatment.Because physiology and the physiopathology meaning of mGluR need to regulate the new medicine and the compound of mGluR function.
Summary of the invention
We have identified the compound that a class is regulated the mGluR function.On the one hand, the invention provides formula I compound or its pharmacy acceptable salt, hydrate, solvate, optical isomer or its combination,
Wherein:
R
1Be to contain the first ring of the one or more heteroatomic 3-7 that independently is selected from N, O and S, wherein said ring is replaced by one or more B;
R
2And R
3Independently be selected from H, C
1-6-alkyl, C
2-6-alkenyl, C
2-6-alkynyl, aryl, heteroaryl, Heterocyclylalkyl, C
3-8-cycloalkyl, C
1-6-alkyl-aryl, C
1-6-alkyl-heteroaryl, C
1-6-alkyl-Heterocyclylalkyl and C
1-6-alkyl-C
3-8-cycloalkyl, wherein R
2And R
3Can be replaced by one or more A;
R
4And R
6Independently be selected from H, hydroxyl, F, Cl, Br, I, nitro, cyano group, C
1-6-alkyl, C
1-6-haloalkyl, OC
1-6Alkyl, OC
1-6-haloalkyl, C
2-6-alkenyl, OC
2-6-alkenyl, C
2-6-alkynyl, OC
2-6-alkynyl, C
3-8-cycloalkyl, C
1-6-alkyl-C
3-8-cycloalkyl, OC
0-6-alkyl-C
3-8-cycloalkyl, aryl, C
1-6-alkylaryl, OC
0-6-alkylaryl, (CO) R
10, O (CO) R
10, O (CO) OR
10, C (O) OR
10, O (CNR
10) OR
11, C
1-6-alkyl OR
10, OC
2-6-alkyl OR
10, C
1-6-alkyl (CO) R
10, OC
1-6-alkyl (CO) R
10, C
0-6-alkyl CO
2R
10, OC
1-6-alkyl CO
2R
10, C
1-6-alkyl cyano group, OC
2-6-alkyl cyano group, C
0-6-alkyl NR
10R
11, OC
2-6-alkyl NR
10R
11, C
1-6-alkyl (CO) NR
10R
11, OC
1-6-alkyl (CO) NR
10R
11, C
0-6-alkyl NR
10(CO) R
11, OC
2-6-alkyl NR
10(CO) R
11, C
0-6-alkyl NR
10(CO) NR
10R
11, C
0-6-alkyl SR
10, OC
2-6-alkyl SR
10, C
0-6-alkyl (SO) R
10, OC
2-6-alkyl (SO) R
10, C
0-6-alkyl SO
2R
10, OC
2-6-alkyl SO
2R
10, C
0-6-alkyl (SO
2) NR
10R
11, OC
2-6-alkyl (SO
2) NR
10R
11, C
0-6-alkyl NR
10(SO
2) R
11, OC
2-6-alkyl NR
10(SO
2) R
11, C
0-6-alkyl NR
10(SO
2) NR
10R
11, OC
2-6-alkyl NR
10(SO
2) NR
10R
11, (CO) NR
10R
11, O (CO) NR
10R
11, NR
10OR
11, C
0-6-alkyl NR
10(CO) OR
11, OC
2-6-alkyl NR
10(CO) OR
11, SO
3R
10With can contain the one or more heteroatomic 5-7 unit ring that independently is selected from N, O and S, wherein R
4And R
6Can be replaced by one or more A and wherein any cycloalkyl or aryl optional with can contain the one or more heteroatomic 5-7 unit that independently is selected from C, N, O and S and encircle and condense;
R
5Be selected from H, F, Cl, Br, I, nitro, CN, C
1-6-alkyl, OC
0-6-alkyl, C
1-6-haloalkyl, OC
1-6-haloalkyl, C
2-6-alkenyl, OC
2-6-alkenyl, C
2-6-alkynyl, OC
2-6-alkynyl, C
3-8Cycloalkyl, C
1-6-alkyl-C
3-8-cycloalkyl, OC
0-6-alkyl-C
3-8-cycloalkyl, aryl, C
1-6-alkylaryl, C
1-6-miscellaneous alkyl aryl, OC
1-6-alkylaryl, OC
1-6-miscellaneous alkyl aryl, C
1-6-alkyl heterocycle alkyl, O Heterocyclylalkyl, OC
1-6-alkyl heterocycle alkyl, C (O) H, (CO) R
10, O (CO) R
10, O (CO) OR
10, C (O) OR
10, O (CN) OR
10, C
1-6-alkyl OR
10, OC
2-6-alkyl OR
10, C
1-6-alkyl (CO) R
10, OC
1-6-alkyl (CO) R
10, C
0-6-alkyl CO
2R
10, C
1-6-alkyl cyano group, OC
2-6-alkyl cyano group, C
0-6-alkyl NR
10R
11, OC
2-6-alkyl NR
10R
11, C
1-6-alkyl (CO) NR
10R
11, OC
1-6-alkyl (CO) NR
10R
11, C
0-6-alkyl NR
10(CO) R
11, OC
2-6-alkyl NR
10(CO) R
11, C
0-6-alkyl NR
10(CO) NR
10R
11, C
0-6-alkyl SR
10, OC
2-6-alkyl SR
10, C
0-6-alkyl (SO) R
10, OC
2-6-alkyl (SO) R
10, C
0-6-alkyl SO
2R
10, OC
2-6-alkyl SO
2R
10, C
0-6-alkyl (SO
2) NR
10R
11, OC
2-6-alkyl (SO
2) NR
10R
11, C
0-6-alkyl NR
10(SO
2) R
11, OC
2-6-alkyl NR
10(SO
2) R
11, C
0-6-alkyl NR
10(SO
2) NR
10R
11, OC
2-6-alkyl NR
10(SO
2) NR
10R
11, (CO) NR
10R
11, O (CO) NR
10R
11, NR
10OR
11, C
0-6-alkyl NR
10(CO) OR
11, OC
2-6-alkyl NR
10(CO) OR
11, SO
3R
10With can contain the one or more heteroatomic 5-7 unit ring that independently is selected from N, O and S, wherein R
5Can be replaced by one or more A and wherein any loop section optional with can contain the one or more heteroatomic 5-7 unit that independently is selected from C, N, O and S and encircle and condense;
R
7Be selected from H, F, Cl, Br, I, nitro, cyano group, OC
1-4-alkyl, C
1-6-alkyl, C
1-6-haloalkyl, OC
1-6-haloalkyl, C
2-6-alkenyl, OC
2-6-alkenyl, C
2-6-alkynyl, OC
2-6-alkynyl and C
3-8-cycloalkyl;
R
8And R
9Independently be selected from H, F, Cl, Br, I, nitro, cyano group, C
1-6-alkyl, C
1-6-haloalkyl, OC
1-6Alkyl, OC
1-6-haloalkyl, C
2-6-alkenyl, OC
2-6-alkenyl, C
2-6-alkynyl and OC
2-6-alkynyl, perhaps, wherein n is greater than 1, the two or more R on the adjacent carbons
8And/or R
9Can not exist, form alkenyl or alkynyl part;
R
10And R
11Independently be selected from H, hydroxyl, oxo, F, Cl, Br, I, nitro, cyano group, C
1-6-alkyl, C
1-6-haloalkyl, OC
1-6Alkyl, OC
1-6-haloalkyl, C
2-6-alkenyl, OC
2-6-alkenyl, C
2-6-alkynyl, OC
2-6-alkynyl, C
3-8-cycloalkyl, C
1-6-alkyl-C
3-8-cycloalkyl, OC
0-6-alkyl-C
3-8-cycloalkyl, aryl, C
1-6-alkylaryl, OC
0-6-alkylaryl, C
0-6-alkyl-Heterocyclylalkyl, OC
1-6-alkyl-Heterocyclylalkyl, heteroaryl and C
1-6Miscellaneous alkyl aryl, wherein any loop section is chosen wantonly and can be contained first ring of the one or more heteroatomic 5-7 that independently is selected from C, N, O and S and condenses and the optional substituting group replacement that is selected from alkyl, halogeno-group, hydroxyl, O alkyl, haloalkyl and O haloalkyl of any loop section;
A is selected from H, hydroxyl, F, Cl, Br, I, nitro, cyano group, oxo, C
1-6-alkyl, C
1-6-haloalkyl, OC
1-6Alkyl, OC
1-6-haloalkyl, C
2-6-alkenyl, OC
2-6-alkenyl, C
2-6-alkynyl, OC
2-6-alkynyl, C
3-8-cycloalkyl, C
1-6-alkyl-C
3-8-cycloalkyl, OC
0-6-alkyl-C
3-8-cycloalkyl, aryl, C
1-6-alkylaryl, OC
0-6-alkylaryl, C
1-6-alkyl-heterocyclic radical, C
1-6-alkyl-Heterocyclylalkyl, OC
0-6-alkyl-Heterocyclylalkyl, (CO) R
10, O (CO) R
10, O (CO) OR
10, O (CNR
10) OR
11, C
1-6-alkyl OR
10, OC
2-6-alkyl OR
10, C
1-6-alkyl (CO) R
10, OC
1-6-alkyl (CO) R
10, C
0-6-alkyl CO
2R
10, OC
1-6-alkyl CO
2R
10, C
1-6-alkyl cyano group, OC
2-6-alkyl cyano group, C
0-6-alkyl NR
10R
11, OC
2-6-alkyl NR
10R
11, C
0-6-alkyl (CO) NR
10R
11, OC
1-6-alkyl (CO) NR
10R
11, C
0-6-alkyl NR
10(CO) R
11, OC
2-6-alkyl NR
10(CO) R
11, C
0-6-alkyl NR
10(CO) NR
10R
11, C
0-6-alkyl SR
10, OC
2-6-alkyl SR
10, C
0-6-alkyl (SO) R
10, OC
2-6-alkyl (SO) R
10, C
1-6-alkyl SO
2R
10, OC
2-6-alkyl SO
2R
10, C
0-6-alkyl (SO
2) NR
10R
11, OC
2-6-alkyl (SO
2) NR
10R
11, C
0-6-alkyl NR
10(SO
2) R
11, OC
2-6-alkyl NR
10(SO
2) R
11, C
0-6-alkyl NR
10(SO
2) NR
10R
11, OC
2-6-alkyl NR
10(SO
2) NR
10R
11, (CO) NR
10R
11, O (CO) NR
10R
11, NR
10OR
11, C
0-6-alkyl NR
10(CO) OR
11, OC
2-6-alkyl NR
10(CO) OR
11, SO
3R
10With can contain the one or more heteroatomic 5-7 unit ring that independently is selected from N, O and S, wherein said 5-7 unit ring is optional by one or more R
10And R
11Replace;
B is selected from C
3-8-cycloalkyl, C
1-6-alkyl-C
3-8-cycloalkyl, OC
0-6-alkyl-C
3-8-cycloalkyl, C
0-6-alkylaryl, OC
0-6-alkylaryl, C
1-6-alkyl-Heterocyclylalkyl, C
1-6-alkyl-Heterocyclylalkyl, OC
0-6-alkyl-Heterocyclylalkyl, C
0-6-alkyl-heteroaryl and OC
0-6-alkyl-heteroaryl, wherein any loop section is selected from halogeno-group, alkyl, haloalkyl, hydroxyl, alkoxyl group, oxo, COR, CO
2R, SO
2At least one substituting group of R and CN replaces;
With
N is selected from 1,2,3,4,5,6,7 and 8;
Prerequisite is that described compound is not:
2-[4-(4-fluoro-phenoxy group)-benzyl]-2,3-dihydro-isoindole-1-ketone;
2-[4-(4-trifluoromethyl-phenoxy group)-benzyl]-2,3-dihydro-isoindole-1-ketone;
2-{3-[4-(4-fluoro-phenoxy group)-phenyl]-propyl group }-7-iodo-2,3-dihydro-isoindole-1-ketone, or
7-iodo-2-[3-(2-methoxyl group-phenoxy group)-benzyl]-2,3-dihydro-isoindole-1-ketone.
The present invention also provides formula I the preparation method of compound.
The present invention also provides the medicinal compositions according to the compound of formula I that contains with pharmaceutically acceptable carrier or vehicle; On the other hand, the invention provides L-glutamic acid dysfunction related neural disease of the animal for the treatment of or need preventing to treat like this and the method for psychiatric disorders.This method comprises the formula I compound that gives the treatment of animals significant quantity or the step of its medicinal compositions.
The present invention also provides formula I compound or its pharmacy acceptable salt or solvate to be used for the treatment of purposes in the medicine of any disease as herein described in preparation.In addition, the invention provides formula I compound or its pharmacy acceptable salt or the solvate that is used for the treatment of.
Detailed Description Of The Invention
The present invention is based on the discovery that shows as the active compound of metabotropic glutamate receptor modulators.More particularly, compound of the present invention shows the activity as the synergistic agent of mGluR2 acceptor, and is used for the treatment of, especially as the medicine for the treatment of sick of L-glutamic acid dysfunction related neural and psychiatric disorders.
By quoting in full, P.C.T. is applied for that disclosing of PCT/US2005/028760 is incorporated herein.
Definition
Unless explanation is arranged in this application in addition, the nomenclature that is used for the application is generally according to organic chemistry nomenclature (Pergamon Press, Oxford, 1979) example and the rule described in A, B, C, D, E, F and the H chapter, the rule of its chemical structure name of giving an example and name chemical structure is incorporated into this paper by reference.Randomly, can adopt chemical name program: ACD/ChemSketch, September 5.09 editions/calendar year 2001, contemporary chemical developer, Inc., Toronto, Canada, the title of generation compound.
The term " alkyl " that is used for this paper refers to have, for example, and the straight or branched alkyl of 1-6 carbon atom, and comprise methyl, ethyl, propyl group, sec.-propyl, the tertiary butyl etc.
The term " alkenyl " that is used for this paper refers to have, for example, and the straight or branched alkenyl of 2-6 carbon atom, and comprise vinyl, 1-propenyl, 1-butylene base etc.
The term " alkynyl " that is used for this paper refers to have, for example, and the straight or branched alkynyl of 2-6 carbon atom, and comprise 1-proyl (propargyl), 1-butylene base etc.
The term " cycloalkyl " that is used for this paper refers to have, for example, and the cyclic group of 3-7 carbon atom (it can be substituted), and comprise cyclopropyl, cyclohexyl, cyclohexenyl etc.
The term " Heterocyclylalkyl " that is used for this paper refers to for example, have the first cyclic group (it can be substituted) of at least one heteroatomic 3-7 that is selected from N, S and O, and comprise piperidyl, piperazinyl, pyrrolidyl, tetrahydrofuran base etc.
The term " alkoxyl group " that is used for this paper refers to have, for example, and the straight or branched alkoxyl group of 1-6 carbon atom, and comprise methoxyl group, oxyethyl group, propoxy-, isopropoxy, tert.-butoxy etc.
The term " halogeno-group " that is used for this paper refers to halogen, and comprises the fluoro that is radioactivity and on-radiation form, chloro, bromo, iodo etc.
The term " aryl " that is used for this paper refers to have, for example, and the aromatic group of 5-12 atom, and comprise phenyl, naphthyl etc.
Term " heteroaryl " refers to comprise at least one the heteroatomic aromatic group that is selected from N, S and O, and comprises several groups, and comprises pyridyl, indyl, furyl, benzofuryl, thienyl, benzothienyl, quinolyl, oxazolyl etc.
The term " alkyloyl " that is used for this paper refers to have, for example, and the straight or branched alkyloyl of 2-7 atom, and comprise ethanoyl, propionyl, butyryl radicals etc.
The term " cycloalkenyl group " that is used for this paper refers to have, for example, and the unsaturated cycloalkyl of 4-7 carbon atom, and comprise ring penta-1-thiazolinyl, hexamethylene-1-thiazolinyl etc.
Term " alkylaryl ", " miscellaneous alkyl aryl " and " alkyl-cycloalkyl " refer to by the alkyl of aryl, heteroaryl or cycloalkyl substituted, and comprise 2-styroyl, 3-cyclohexyl propyl group etc.
Term " can contain the first ring of the one or more heteroatomic 5-7 that independently is selected from N, O and S " and comprise aromatics and heteroaromatic rings, and carbocyclic ring and heterocycle, it can be saturated or undersaturated, and comprises furyl, isoxazolyl, oxazolyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidyl, pyrryl, thiazolyl, thienyl, imidazolyl, triazolyl, morpholinyl, piperazinyl, piperidyl, homopiperidinyl, THP trtrahydropyranyl, phenyl, cyclohexyl, suberyl, cyclopentyl, cyclohexyl etc.
Term " pharmacy acceptable salt " refers to be suitable for the acid salt or the base addition salt of patient treatment.
" pharmaceutically-acceptable acid addition " is the basic cpd represented by formula I or any non-toxic organic or the inorganic acid addition salt of its any intermediate.Form the exemplary inorganic acid that is suitable for salt and comprise spirit of salt, Hydrogen bromide, sulfuric acid and phosphoric acid and acid metal salt for example sodium hydrogen phosphate and sal enixum.Forming the exemplary organic acid that is suitable for salt comprises single, double and tricarboxylic acid.For example, this exemplary class acid has acetate, oxyacetic acid, lactic acid, pyruvic acid, propanedioic acid, succsinic acid, pentanedioic acid, fumaric acid, oxysuccinic acid, tartrate, citric acid, xitix, toxilic acid, hydroxymaleic acid, phenylformic acid, hydroxy-benzoic acid, phenylacetic acid, styracin, Whitfield's ointment, 2-phenoxy benzoic acid, tosic acid and other sulfonic acid, for example methylsulfonic acid and 2-ethylenehydrinsulfonic acid.Can form list or diacid salt, this class salt can hydration, solvation or substantially anhydrous form exist.Usually, compare with its free alkali form, the more soluble in water and various hydrophilic organic solvents of the acid salt of these compounds, and show higher fusing point usually.The choice criteria of suitable salt is known to those skilled in the art.For example, other non-pharmacy acceptable salt for example oxalate can be used for the separation of laboratory purposes or the follow-up formula I compound that is converted into pharmaceutically-acceptable acid addition.
" pharmaceutically acceptable base addition salt " is the acidic cpd represented of formula I or any non-toxic organic or the mineral alkali additive salt of its any intermediate.Form the oxyhydroxide that the exemplary inorganic alkali that is suitable for salt comprises lithium, sodium, potassium, calcium, magnesium or barium.Form the exemplary organic bases that is suitable for salt and comprise aliphatics, alicyclic or aromatics organic amine, for example methylamine, Trimethylamine 99 and picoline or ammonia.The selection of suitable salt can be important, so that the ester functional group (if there is) of other position in the molecule is not hydrolyzed.The choice criteria of suitable salt is known to those skilled in the art.
" solvate " refers to the pharmacy acceptable salt of formula I compound or formula I compound, and wherein the molecule of suitable solvents is incorporated in the lattice.Suitable solvents under the dosage that gives as solvate is can tolerate on the physiology.The example of the solvent that is suitable for has ethanol, water etc.When water was solvent, this molecule was called as hydrate.
Term " steric isomer " is the general term at distinguishing all isomer aspect its atoms in space location at unique molecular.It comprises mirror image isomer (enantiomer), how much (cis/trans) isomer and has more than one is not the isomer (diastereomer) of compound of the chiral centre of mutual mirror image.
Term " processing " or " treatment " refers to that the appearance of the symptom of specified illness or disease is perhaps prevented or slowed down to temporarily or for good and all relief of symptoms, symptomatolytic reason.
Term " treatment significant quantity " refers to effectively treat the amount of the compound of specified illness or disease.
Term " pharmaceutically acceptable carrier " refers to innoxious solvent, dispersion agent, vehicle, adjuvant or mixes so that medicinal compositions promptly, can give other raw material that patient's formulation forms with activeconstituents.An example of this class carrier is the pharmaceutically acceptable oil that generally is used as administered parenterally.
Compound:
The compounds of this invention meets formula I usually:
Wherein:
R
1Be to contain the first ring of the one or more heteroatomic 3-7 that independently is selected from N, O and S, wherein said ring is replaced by one or more B;
R
2And R
3Independently be selected from H, C
1-6-alkyl, C
2-6-alkenyl, C
2-6-alkynyl, aryl, heteroaryl, Heterocyclylalkyl, C
3-8-cycloalkyl, C
1-6-alkyl-aryl, C
1-6-alkyl-heteroaryl, C
1-6-alkyl-Heterocyclylalkyl and C
1-6-alkyl-C
3-8-cycloalkyl, wherein R
2And R
3Can be replaced by one or more A;
R
4And R
6Independently be selected from H, hydroxyl, F, Cl, Br, I, nitro, cyano group, C
1-6-alkyl, C
1-6-haloalkyl, OC
1-6Alkyl, OC
1-6-haloalkyl, C
2-6-alkenyl, OC
2-6-alkenyl, C
2-6-alkynyl, OC
2-6-alkynyl, C
3-8-cycloalkyl, C
1-6-alkyl-C
3-8-cycloalkyl, OC
0-6-alkyl-C
3-8-cycloalkyl, aryl, C
1-6-alkylaryl, OC
0-6-alkylaryl, (CO) R
10, O (CO) R
10, O (CO) OR
10, C (O) OR
10, O (CNR
10) OR
11, C
1-6-alkyl OR
10, OC
2-6-alkyl OR
10, C
1-6-alkyl (CO) R
10, OC
1-6-alkyl (CO) R
10, C
0-6-alkyl CO
2R
10, OC
1-6-alkyl CO
2R
10, C
1-6-alkyl cyano group, OC
2-6-alkyl cyano group, C
0-6-alkyl NR
10R
11, OC
2-6-alkyl NR
10R
11, C
1-6-alkyl (CO) NR
10R
11, OC
1-6-alkyl (CO) NR
10R
11, C
0-6-alkyl NR
10(CO) R
11, OC
2-6-alkyl NR
10(CO) R
11, C
0-6-alkyl NR
10(CO) NR
10R
11, C
0-6-alkyl SR
10, OC
2-6-alkyl SR
10, C
0-6-alkyl (SO) R
10, OC
2-6-alkyl (SO) R
10, C
0-6-alkyl SO
2R
10, OC
2-6-alkyl SO
2R
10, C
0-6-alkyl (SO
2) NR
10R
11, OC
2-6-alkyl (SO
2) NR
10R
11, C
0-6-alkyl NR
10(SO
2) R
11, OC
2-6-alkyl NR
10(SO
2) R
11, C
0-6-alkyl NR
10(SO
2) NR
10R
11, OC
2-6-alkyl NR
10(SO
2) NR
10R
11, (CO) NR
10R
11, O (CO) NR
10R
11, NR
10OR
11, C
0-6-alkyl NR
10(CO) OR
11, OC
2-6-alkyl NR
10(CO) OR
11, SO
3R
10With can contain the one or more heteroatomic 5-7 unit ring that independently is selected from N, O and S, wherein R
4And R
6Can be replaced by one or more A and wherein any cycloalkyl or aryl optional with can contain the one or more heteroatomic 5-7 unit that independently is selected from C, N, O and S and encircle and condense;
R
5Be selected from H, F, Cl, Br, I, nitro, CN, C
1-6-alkyl, OC
0-6-alkyl, C
1-6-haloalkyl, OC
1-6-haloalkyl, C
2-6-alkenyl, OC
2-6-alkenyl, C
2-6-alkynyl, OC
2-6-alkynyl, C
3-8-cycloalkyl, C
1-6-alkyl-C
3-8-cycloalkyl, OC
0-6-alkyl-C
3-8-cycloalkyl, aryl, C
1-6-alkylaryl, C
1-6-miscellaneous alkyl aryl, OC
1-6-alkylaryl, OC
1-6-miscellaneous alkyl aryl, C
1-6-alkyl heterocycle alkyl, O Heterocyclylalkyl, OC
1-6-alkyl heterocycle alkyl, C (O) H, (CO) R
10, O (CO) R
10, O (CO) OR
10, C (O) OR
10, O (CN) OR
10, C
1-6-alkyl OR
10, OC
2-6-alkyl OR
10, C
1-6-alkyl (CO) R
10, OC
1-6-alkyl (CO) R
10, C
0-6-alkyl CO
2R
10, C
1-6-alkyl cyano group, OC
2-6-alkyl cyano group, C
0-6-alkyl NR
10R
11, OC
2-6-alkyl NR
10R
11, C
1-6-alkyl (CO) NR
10R
11, OC
1-6-alkyl (CO) NR
10R
11, C
0-6-alkyl NR
10(CO) R
11, OC
2-6-alkyl NR
10(CO) R
11, C
0-6-alkyl NR
10(CO) NR
10R
11, C
0-6-alkyl SR
10, OC
2-6-alkyl SR
10, C
0-6-alkyl (SO) R
10, OC
2-6-alkyl (SO) R
10, C
0-6-alkyl SO
2R
10, OC
2-6-alkyl SO
2R
10, C
0-6-alkyl (SO
2) NR
10R
11, OC
2-6-alkyl (SO
2) NR
10R
11, C
0-6-alkyl NR
10(SO
2) R
11, OC
2-6-alkyl NR
10(SO
2) R
11, C
0-6-alkyl NR
10(SO
2) NR
10R
11, OC
2-6-alkyl NR
10(SO
2) NR
10R
11, (CO) NR
10R
11, O (CO) NR
10R
11, NR
10OR
11, C
0-6-alkyl NR
10(CO) OR
11, OC
2-6-alkyl NR
10(CO) OR
11, SO
3R
10With can contain the one or more heteroatomic 5-7 unit ring that independently is selected from N, O and S, wherein R
5Can be replaced by one or more A and wherein any loop section optional with can contain the one or more heteroatomic 5-7 unit that independently is selected from C, N, O and S and encircle and condense;
R
7Be selected from H, F, Cl, Br, I, nitro, cyano group, OC
1-4-alkyl, C
1-6-alkyl, C
1-6-haloalkyl, OC
1-6-haloalkyl, C
2-6-alkenyl, OC
2-6-alkenyl, C
2-6-alkynyl, OC
2-6-alkynyl and C
3-8-cycloalkyl;
R
8And R
9Independently be selected from H, F, Cl, Br, I, nitro, cyano group, C
1-6-alkyl, C
1-6-haloalkyl, OC
1-6Alkyl, OC
1-6-haloalkyl, C
2-6-alkenyl, OC
2-6-alkenyl, C
2-6-alkynyl and OC
2-6-alkynyl, perhaps, wherein n is greater than 1, the two or more R on the adjacent carbons
8And/or R
9Can not exist, form alkenyl or alkynyl part;
R
10And R
11Independently be selected from H, hydroxyl, oxo, F, Cl, Br, I, nitro, cyano group, C
1-6-alkyl, C
1-6-haloalkyl, OC
1-6Alkyl, OC
1-6-haloalkyl, C
2-6-alkenyl, OC
2-6-alkenyl, C
2-6-alkynyl, OC
2-6-alkynyl, C
3-8-cycloalkyl, C
1-6-alkyl-C
3-8-cycloalkyl, OC
0-6-alkyl-C
3-8-cycloalkyl, aryl, C
1-6-alkylaryl, OC
0-6-alkylaryl, C
0-6-alkyl-Heterocyclylalkyl, OC
1-6-alkyl-Heterocyclylalkyl, heteroaryl and C
1-6Miscellaneous alkyl aryl, wherein any loop section is chosen wantonly and can be contained first ring of the one or more heteroatomic 5-7 that independently is selected from C, N, O and S and condenses and the optional substituting group replacement that is selected from alkyl, halogeno-group, hydroxyl, O alkyl, haloalkyl and O haloalkyl of any loop section;
A is selected from H, hydroxyl, F, Cl, Br, I, nitro, cyano group, oxo, C
1-6-alkyl, C
1-6-haloalkyl, OC
1-6Alkyl, OC
1-6-haloalkyl, C
2-6-alkenyl, OC
2-6-alkenyl, C
2-6-alkynyl, OC
2-6-alkynyl, C
3-8-cycloalkyl, C
1-6-alkyl-C
3-8-cycloalkyl, OC
0-6-alkyl-C
3-8-cycloalkyl, aryl, C
1-6-alkylaryl, OC
0-6-alkylaryl, C
1-6-alkyl-heterocyclic radical, C
1-6-alkyl-Heterocyclylalkyl, OC
0-6-alkyl-Heterocyclylalkyl, (CO) R
10, O (CO) R
10, O (CO) OR
10, O (CNR
10) OR
11, C
1-6-alkyl OR
10, OC
2-6-alkyl OR
10, C
1-6-alkyl (CO) R
10, OC
1-6-alkyl (CO) R
10, C
0-6-alkyl CO
2R
10, OC
1-6-alkyl CO
2R
10, C
1-6-alkyl cyano group, OC
2-6-alkyl cyano group, C
0-6-alkyl NR
10R
11, OC
2-6-alkyl NR
10R
11, C
0-6-alkyl (CO) NR
10R
11, OC
1-6-alkyl (CO) NR
10R
11, C
0-6-alkyl NR
10(CO) R
11, OC
2-6-alkyl NR
10(CO) R
11, C
0-6-alkyl NR
10(CO) NR
10R
11, C
0-6-alkyl SR
10, OC
2-6-alkyl SR
10, C
0-6-alkyl (SO) R
10, OC
2-6-alkyl (SO) R
10, C
1-6-alkyl SO
2R
10, OC
2-6-alkyl SO
2R
10, C
0-6-alkyl (SO
2) NR
10R
11, OC
2-6-alkyl (SO
2) NR
10R
11, C
0-6-alkyl NR
10(SO
2) R
11, OC
2-6-alkyl NR
10(SO
2) R
11, C
0-6-alkyl NR
10(SO
2) NR
10R
11, OC
2-6-alkyl NR
10(SO
2) NR
10R
11, (CO) NR
10R
11, O (CO) NR
10R
11, NR
10OR
11, C
0-6-alkyl NR
10(CO) OR
11, OC
2-6-alkyl NR
10(CO) OR
11, SO
3R
10With can contain the one or more heteroatomic 5-7 unit ring that independently is selected from N, O and S, wherein said 5-7 unit ring is optional by one or more R
10And R
11Replace;
B is selected from C
3-8-cycloalkyl, C
1-6-alkyl-C
3-8-cycloalkyl, OC
0-6-alkyl-C
3-8-cycloalkyl, C
0-6-alkylaryl, OC
0-6-alkylaryl, C
1-6-alkyl-Heterocyclylalkyl, C
1-6-alkyl-Heterocyclylalkyl, OC
0-6-alkyl-Heterocyclylalkyl, C
0-6-alkyl-heteroaryl and OC
0-6-alkyl-heteroaryl, wherein any loop section is selected from halogeno-group, alkyl, haloalkyl, hydroxyl, alkoxyl group, oxo, COR, CO
2R, SO
2At least one substituting group of R and CN replaces and n is selected from 1,2,3,4,5,6,7 and 8;
Or its pharmacy acceptable salt, hydrate, solvate, optical isomer or its combination;
Prerequisite is that described compound is not:
2-[4-(4-fluoro-phenoxy group)-benzyl]-2,3-dihydro-isoindole-1-ketone;
2-[4-(4-trifluoromethyl-phenoxy group)-benzyl]-2,3-dihydro-isoindole-1-ketone;
2-{3-[4-(4-fluoro-phenoxy group)-phenyl]-propyl group }-7-iodo-2,3-dihydro-isoindole-1-ketone, or
7-iodo-2-[3-(2-methoxyl group-phenoxy group)-benzyl]-2,3-dihydro-isoindole-1-ketone.
Special compound or its pharmacy acceptable salt, hydrate, solvate, optical isomer or its combination according to formula I are those compounds, wherein:
R
1Be phenyl, wherein said phenyl is replaced by one or more B;
R
2And R
3Independently be selected from H, C
1-6-alkyl, C
2-6-alkenyl, C
2-6-alkynyl, aryl, heteroaryl, Heterocyclylalkyl, C
3-8-cycloalkyl, C
1-6-alkyl-aryl, C
1-6-alkyl-heteroaryl, C
1-6-alkyl-Heterocyclylalkyl and C
1-6-alkyl-C
3-8-cycloalkyl, wherein R
2And R
3Can be replaced by one or more A;
R
4And R
6Independently be selected from H, hydroxyl, F, Cl, Br, I, nitro, cyano group, C
1-6-alkyl, C
1-6-haloalkyl, OC
1-6Alkyl, OC
1-6-haloalkyl, C
2-6-alkenyl, OC
2-6-alkenyl, C
2-6-alkynyl, OC
2-6-alkynyl, C
3-8-cycloalkyl, C
1-6-alkyl-C
3-8-cycloalkyl, OC
0-6-alkyl-C
3-8-cycloalkyl, aryl, C
1-6-alkylaryl, OC
0-6-alkylaryl, (CO) R
10, O (CO) R
10, O (CO) OR
10, C (O) OR
10, O (CNR
10) OR
11, C
1-6-alkyl OR
10, OC
2-6-alkyl OR
10, C
1-6-alkyl (CO) R
10, OC
1-6-alkyl (CO) R
10, C
0-6-alkyl CO
2R
10, OC
1-6-alkyl CO
2R
10, C
1-6-alkyl cyano group, OC
2-6-alkyl cyano group, C
0-6-alkyl NR
10R
11, OC
2-6-alkyl NR
10R
11, C
1-6-alkyl (CO) NR
10R
11, OC
1-6-alkyl (CO) NR
10R
11, C
0-6-alkyl NR
10(CO) R
11, OC
2-6-alkyl NR
10(CO) R
11, C
0-6-alkyl NR
10(CO) NR
10R
11, C
0-6-alkyl SR
10, OC
2-6-alkyl SR
10, C
0-6-alkyl (SO) R
10, OC
2-6-alkyl (SO) R
10, C
0-6-alkyl SO
2R
10, OC
2-6-alkyl SO
2R
10, C
0-6-alkyl (SO
2) NR
10R
11, OC
2-6-alkyl (SO
2) NR
10R
11, C
0-6-alkyl NR
10(SO
2) R
11, OC
2-6-alkyl NR
10(SO
2) R
11, C
0-6-alkyl NR
10(SO
2) NR
10R
11, OC
2-6-alkyl NR
10(SO
2) NR
10R
11, (CO) NR
10R
11, O (CO) NR
10R
11, NR
10OR
11, C
0-6-alkyl NR
10(CO) OR
11, OC
2-6-alkyl NR
10(CO) OR
11, SO
3R
10With can contain the one or more heteroatomic 5-7 unit ring that independently is selected from N, O and S, wherein R
4And R
6Can be replaced by one or more A and wherein any cycloalkyl or aryl optional with can contain the one or more heteroatomic 5-7 unit that independently is selected from C, N, O and S and encircle and condense;
R
5Be selected from H, F, Cl, Br, I, nitro, CN, C
1-6-alkyl, OC
0-6-alkyl, C
1-6-haloalkyl, OC
1-6-haloalkyl, C
2-6-alkenyl, OC
2-6-alkenyl, C
2-6-alkynyl, OC
2-6-alkynyl, C
3-8-cycloalkyl, C
1-6-alkyl-C
3-8-cycloalkyl, OC
0-6-alkyl-C
3-8-cycloalkyl, aryl, C
1-6-alkylaryl, C
1-6-miscellaneous alkyl aryl, OC
1-6-alkylaryl, OC
1-6-miscellaneous alkyl aryl, C
1-6-alkyl heterocycle alkyl, O Heterocyclylalkyl, OC
1-6-alkyl heterocycle alkyl, C (O) H, (CO) R
10, O (CO) R
10, O (CO) OR
10, C (O) OR
10, O (CN) OR
10, C
1-6-alkyl OR
10, OC
2-6-alkyl OR
10, C
1-6-alkyl (CO) R
10, OC
1-6-alkyl (CO) R
10, C
0-6-alkyl CO
2R
10, C
1-6-alkyl cyano group, OC
2-6-alkyl cyano group, C
0-6-alkyl NR
10R
11, OC
2-6-alkyl NR
10R
11, C
1-6-alkyl (CO) NR
10R
11, OC
1-6-alkyl (CO) NR
10R
11, C
0-6-alkyl NR
10(CO) R
11, OC
2-6-alkyl NR
10(CO) R
11, C
0-6-alkyl NR
10(CO) NR
10R
11, C
0-6-alkyl SR
10, OC
2-6-alkyl SR
10, C
0-6-alkyl (SO) R
10, OC
2-6-alkyl (SO) R
10, C
0-6-alkyl SO
2R
10, OC
2-6-alkyl SO
2R
10, C
0-6-alkyl (SO
2) NR
10R
11, OC
2-6-alkyl (SO
2) NR
10R
11, C
0-6-alkyl NR
10(SO
2) R
11, OC
2-6-alkyl NR
10(SO
2) R
11, C
0-6-alkyl NR
10(SO
2) NR
10R
11, OC
2-6-alkyl NR
10(SO
2) NR
10R
11, (CO) NR
10R
11, O (CO) NR
10R
11, NR
10OR
11, C
0-6-alkyl NR
10(CO) OR
11, OC
2-6-alkyl NR
10(CO) OR
11, SO
3R
10With can contain the one or more heteroatomic 5-7 unit ring that independently is selected from N, O and S, wherein R
5Can be replaced by one or more A and wherein any loop section optional with can contain the one or more heteroatomic 5-7 unit that independently is selected from C, N, O and S and encircle and condense;
R
7Be selected from H, F, Cl, Br, I, nitro, cyano group, OC
1-4-alkyl, C
1-6-alkyl, C
1-6-haloalkyl, OC
1-6-haloalkyl, C
2-6-alkenyl, OC
2-6-alkenyl, C
2-6-alkynyl, OC
2-6-alkynyl and C
3-8-cycloalkyl;
R
8And R
9All be H;
R
10And R
11Independently be selected from H, hydroxyl, oxo, F, Cl, Br, I, nitro, cyano group, C
1-6-alkyl, C
1-6-haloalkyl, OC
1-6Alkyl, OC
1-6-haloalkyl, C
2-6-alkenyl, OC
2-6-alkenyl, C
2-6-alkynyl, OC
2-6-alkynyl, C
3-8-cycloalkyl, C
1-6-alkyl-C
3-8-cycloalkyl, OC
0-6-alkyl-C
3-8-cycloalkyl, aryl, C
1-6-alkylaryl, OC
0-6-alkylaryl, C
0-6-alkyl-Heterocyclylalkyl, OC
1-6-alkyl-Heterocyclylalkyl, heteroaryl and C
1-6Miscellaneous alkyl aryl, wherein any loop section is chosen wantonly and can be contained first ring of the one or more heteroatomic 5-7 that independently is selected from C, N, O and S and condenses and the optional substituting group replacement that is selected from alkyl, halogeno-group, hydroxyl, O alkyl, haloalkyl and O haloalkyl of any loop section;
A is selected from H, hydroxyl, F, Cl, Br, I, nitro, cyano group, oxo, C
1-6-alkyl, C
1-6-haloalkyl, OC
1-6Alkyl, OC
1-6-haloalkyl, C
2-6-alkenyl, OC
2-6-alkenyl, C
2-6-alkynyl, OC
2-6-alkynyl, C
3-8-cycloalkyl, C
1-6-alkyl-C
3-8-cycloalkyl, OC
0-6-alkyl-C
3-8-cycloalkyl, aryl, C
1-6-alkylaryl, OC
0-6-alkylaryl, C
1-6-alkyl-heterocyclic radical, C
1-6-alkyl-Heterocyclylalkyl, OC
0-6-alkyl-Heterocyclylalkyl, (CO) R
10, O (CO) R
10, O (CO) OR
10, O (CNR
10) OR
11, C
1-6-alkyl OR
10, OC
2-6-alkyl OR
10, C
1-6-alkyl (CO) R
10, OC
1-6-alkyl (CO) R
10, C
0-6-alkyl CO
2R
10, OC
1-6-alkyl CO
2R
10, C
1-6-alkyl cyano group, OC
2-6-alkyl cyano group, C
0-6-alkyl NR
10R
11, OC
2-6-alkyl NR
10R
11, C
0-6-alkyl (CO) NR
10R
11, OC
1-6-alkyl (CO) NR
10R
11, C
0-6-alkyl NR
10(CO) R
11, OC
2-6-alkyl NR
10(CO) R
11, C
0-6-alkyl NR
10(CO) NR
10R
11, C
0-6-alkyl SR
10, OC
2-6-alkyl SR
10, C
0-6-alkyl (SO) R
10, OC
2-6-alkyl (SO) R
10, C
1-6-alkyl SO
2R
10, OC
2-6-alkyl SO
2R
10, C
0-6Alkyl (SO
2) NR
10R
11, OC
2-6Alkyl (SO
2) NR
10R
11, O
0-6Alkyl NR
10(SO
2) R
11, OC
2-6-alkyl NR
10(SO
2) R
11, C
0-6-alkyl NR
10(SO
2) NR
10R
11, OC
2-6-alkyl NR
10(SO
2) NR
10R
11, (CO) NR
10R
11, O (CO) NR
10R
11, NR
10OR
11, C
0-6-alkyl NR
10(CO) OR
11, OC
2-6-alkyl NR
10(CO) OR
11, SO
3R
10With can contain the one or more heteroatomic 5-7 unit ring that independently is selected from N, O and S, wherein said 5-7 unit ring is optional by one or more R
10And R
11Replace;
B is selected from C
0-6-alkylaryl and OC
0-6-alkylaryl, wherein any aryl moiety is selected from halogeno-group, alkyl, haloalkyl, hydroxyl, alkoxyl group, oxo, COR, CO
2R, SO
2At least one substituting group of R and CN replaces;
With
N is 1.
Other special compound or its pharmacy acceptable salt, hydrate, solvate, optical isomer or its combination according to formula I are those compounds, wherein:
R
1Be phenyl, wherein said phenyl is replaced by one or more B;
R
2And R
3Independently be selected from H and C
1-6-alkyl;
R
4Be H, and R
6Be selected from H, hydroxyl, F, Cl, Br, I, nitro, cyano group, C
1-6-alkyl and OC
1-6Alkyl;
R
5Be selected from H, F, Cl, Br, I and maybe can contain the first ring of the one or more heteroatomic 5-7 that independently is selected from N, O and S;
R
7Be selected from H or C
1-6-alkyl;
R
8And R
9All be H;
B is OC
0-6At least one substituting group that-alkylaryl, wherein said aryl moiety are selected from halogeno-group, alkyl, haloalkyl and alkoxyl group replaces,
With
N is 1.
Other compound of the present invention generally meets formula I:
R wherein
1, R
2, R
3, R
4, R
5, R
6, R
7, R
8, R
9With n as hereinbefore defined.In specific embodiments, n is 1,2 or 3.When n greater than 1 the time, the two or more R on the adjacent carbons
8And R
9Can not exist, so that form fractional saturation or complete undersaturated part.Therefore, for example, when n is 2 and two adjacent R
8And R
9When not existing, this part is an alkenyl.As four adjacent R
8And R
9When not existing, this part is an alkynyl.Comprise all these combinations.The most especially, n is 1.In the present context, R
8And R
9Respectively be H especially.
The compound of another special subgroup is the R among its Chinese style I
4And R
6Respectively be those compounds of H.Therefore, the aromatics part of isoindolone nuclear can be replaced by two at the most in this embodiment.
In another embodiment, R
1Be to be selected from optional be selected from F, Cl, Br, I, OC
1-6-haloalkyl and OC
0-6Aryl, C that one or more A of-alkylaryl replace
3-8The 5-7 unit ring of-cycloalkyl, cycloalkenyl group and heterocyclic radical.Exemplary loop in this context includes, but not limited to phenyl, naphthyl, C
3-8-cycloalkyl, cycloalkenyl group, furyl, tetrahydrofuran base, thienyl, pyridyl, oxadiazole base, quinolyl, piperazinyl and THP trtrahydropyranyl.Especially, R
1Be optional be selected from F, Cl, Br, I, OC
1-6-haloalkyl and OC
0-6The phenyl that one or more A of-alkylaryl replace.
In another embodiment, R
1Be optional be selected from F, Cl, Br, I, OC
1-6-haloalkyl and OC
0-6The phenyl that one or more A of-alkylaryl replace.In addition, R
2, R
3, R
4, R
6, R
8And R
9Respectively be that H and n are 1.R
7Specific meanings comprise H, Cl, Br, I, C
1-6-alkyl and OC
1-4-alkyl, particularly H, Cl, Br, I ,-CH
3With-OCH
3, and the most particularly Cl, Br, I and-OCH
3
In another embodiment, R
1Be C
3-8-cycloalkyl.Especially, R
1It is cyclopropyl.In this embodiment, n particularly 1,2 or 3 and the most particularly 1.
The another special subgroup of compound is R wherein
5Be selected from C
3-8-cycloalkyl, C
1-6-alkyl-C
3-8-cycloalkyl, OC
0-6-alkyl-C
3-8-cycloalkyl, aryl, C
1-6-alkylaryl, OC
1-6-alkylaryl and those compounds that can contain the first ring of one or more heteroatomic 5-7 that independently is selected from N, O and S.In this embodiment, R
5Can be replaced by one or more A and any cycloalkyl or aryl optional with can contain the one or more heteroatomic 5-7 unit that independently is selected from C, N, O and S and encircle and condense.Especially, R
5Be selected from C
1-6The one or more heteroatomic 5-7 unit that-alkylaryl and can containing independently is selected from N, O and S encircles, wherein R
5Can be replaced by one or more A.More particularly, R
5Be to contain the first ring of the one or more heteroatomic 5-7 that independently is selected from N, O and S, this ring is selected from C
1-6-alkyl-heterocyclic radical replaces with one or more A that can contain the first ring of one or more heteroatomic 5-7 that independently is selected from N, O and S.
In another embodiment, n is 1,2 or 3; R
4, R
6, R
8And R
9Respectively be H; R
1Be selected from optional be selected from F, Cl, Br, I, OC
1-6-haloalkyl and OC
0-6Aryl, C that one or more A of-alkylaryl replace
3-8-cycloalkyl, cycloalkenyl group and heterocyclic radical; R
7Be selected from H, Cl, Br, I, C
1-6-alkyl and OC
1-4-alkyl, and R
5Be selected from C
3-8-cycloalkyl, C
1-6-alkyl-C
3-8-cycloalkyl, OC
0-6-alkyl-C
3-8-cycloalkyl, aryl, C
1-6-alkylaryl, OC
1-6The one or more heteroatomic 5-7 unit that-alkylaryl and can containing independently is selected from N, O and S encircles, wherein R
5Can be replaced by one or more A and wherein any loop section optional with can contain the one or more heteroatomic 5-7 unit that independently is selected from C, N, O and S and encircle and condense.
In another embodiment, n is 1,2 or 3; R
4, R
6, R
8And R
9Respectively be H; R
1Be selected from optional be selected from F, Cl, Br, I, OC
1-6-haloalkyl and OC
0-6Phenyl, naphthyl, C that one or more A of-alkylaryl replace
3-8-cycloalkyl, cycloalkenyl group, furyl, tetrahydrofuran base, thienyl, pyridyl, oxadiazole base, quinolyl, piperazinyl and THP trtrahydropyranyl; R
7Be selected from Cl, Br, I and-OCH
3, and R
5Be selected from C
1-6The one or more heteroatomic 5-7 unit that-alkylaryl and can containing independently is selected from N, O and S encircles, wherein R
5Can be replaced by one or more A.
In another embodiment, n is 1,2 or 3; R
4, R
6, R
8And R
9Respectively be H; R
1Be optional be selected from F, Cl, Br, I, OC
1-6-haloalkyl and OC
0-6The phenyl that one or more A of-alkylaryl replace; R
7Be selected from H, Cl, Br, I, C
1-6-alkyl and OC
1-4-alkyl, and R
5Be to contain the first ring of the one or more heteroatomic 5-7 that independently is selected from N, O and S, the first ring of wherein said 5-7 is selected from C
1-6-alkyl-heterocyclic radical replaces with one or more A that can contain the first ring of one or more heteroatomic 5-7 that independently is selected from N, O and S.
In another embodiment, n is 1; R
2, R
3, R
4, R
6, R
8And R
9Respectively be H; R
1Be optional be selected from F, Cl, Br, I, OC
1-6-haloalkyl and OC
0-6The phenyl that one or more A of-alkylaryl replace; R
7Be selected from Cl, Br, I and-OCH
3, and R
5Be selected from C
1-6The one or more heteroatomic 5-7 unit that-alkylaryl and can containing independently is selected from N, O and S encircles, wherein R
5Can be replaced by one or more A.
It will be readily apparent to those skilled in the art that when The compounds of this invention contains one or more chiral centre The compounds of this invention can be used as enantiomer or diastereomeric form, or as racemic mixture existence and separated.The present invention includes any possible enantiomer, diastereomer, racemic modification or their mixture of formula I compound.For example, can separate, by synthesizing by the optical activity starting raw material or, preparing the optical activity form of The compounds of this invention by asymmetric synthesis based on method described below by the chirality chromatography of racemic modification.
Those skilled in the art can be appreciated that also some The compounds of this invention can be used as geometrical isomer, and for example the E of alkene and Z isomer exist.The present invention includes any geometrical isomer of formula I compound.Be also to be understood that the present invention will comprise the tautomer of formula I compound.
Those skilled in the art also will appreciate that, some The compounds of this invention can solvation, and for example hydration and non-solvent form exist.Be also to be understood that all these kind solvent forms that the present invention includes formula I compound.
The salt of formula I compound also within the scope of the invention.Usually, adopt standard program well known in the art, for example, by making the compound of abundant alkalescence, for example alkylamine and suitable acid, for example, HCl or acetic acidreaction generate acceptable negatively charged ion on the physiology, obtain the pharmacy acceptable salt of The compounds of this invention.Also can be by in water-bearing media, handle with the basic metal of monovalent or alkaline earth metal hydroxides or alkoxide (for example ethylate or methylate) or the alkaline organic amine (for example choline or meglumine) that is suitable for and to have the proper sourness proton, the The compounds of this invention of carboxylic acid or phenol for example, through conventional purification technique, prepare corresponding alkali metal (for example sodium, potassium or lithium) or alkaline-earth metal (for example calcium) salt subsequently.
In one embodiment of the invention, formula I compound can be converted into its pharmacy acceptable salt or solvate, especially, acid salt, for example hydrochloride, hydrobromate, phosphoric acid salt, acetate, fumarate, maleate, tartrate, Citrate trianion, mesylate or tosilate.
Specific example of the present invention comprises compound as herein described, their pharmacy acceptable salt, hydrate, solvate and their optical isomer.
Medicinal compositions:
Compound of the present invention can be mixed with conventional medicinal compositions, and it comprises formula I compound or its pharmacy acceptable salt or solvate with pharmaceutically acceptable carrier or mixed with excipients.Pharmaceutically acceptable carrier can be solid or liquid.But the solid form preparation includes, but not limited to powder, tablet dispersible granule, capsule, cachet and suppository.
Solid carrier can be one or more materials, and they can play the effect of thinner, correctives, solubilizing agent, lubricant, suspension agent, tackiness agent or tablet disintegrant.Solid carrier also can be encapsulated materials.
In the powder, carrier is finely divided solid, and it mixes with finely divided The compounds of this invention or active ingredient.In the tablet, active ingredient is mixed in the proper ratio with the carrier with the bond property that needs and is pressed into needed shape and size.
For the preparation suppository composition, at first melt low melt wax, for example the mixture of glycerin fatty acid ester and theobroma oil passes through again, for example stirs, and activeconstituents is scattered in wherein.The uniform mixture that will melt again injects the suitably mould of size, makes it cooling and curing.
The carrier that is suitable for includes, but not limited to magnesiumcarbonate, Magnesium Stearate, talcum, lactose, sucrose, pectin, dextrin, starch, tragacanth gum, methylcellulose gum, Xylo-Mucine, low melt wax, theobroma oil etc.
The term composition is also planned to comprise the preparation of the active ingredient with the capsular capsulation material that provides as carrier, and active ingredient wherein (having or do not have other carrier) is surrounded by such and its bonded carrier.Similarly, comprise cachet (cachets).
Tablet, powder, cachet and capsule can be used as and be suitable for oral solid dosage.
The liquid form composition comprises solution, suspensoid and emulsion.For example, the sterilized water of active compound or aqueous solution of propylene glycol can be the liquid preparation that is suitable for parenteral admin.Liquid composition also can be formulated into the solution in the polyoxyethylene glycol aqueous solution.
Can be by making solubilization of active ingredient in water, and add appropriate colouring agent, correctives, stablizer and thickening material when needed, prepare oral aqueous solution agent.Can be scattered in and the viscosity raw material by making the active ingredient of segmenting, for example, in other suspension agent water together known to natural synthetic gum, resin, methylcellulose gum, Xylo-Mucine and the medicinal preparations field, prepare oral aqueous suspensions.Oral exemplary composition can contain one or more tinting materials, sweeting agent, correctives and/or sanitas.
Depend on administering mode, medicinal compositions will comprise about 0.05% weight (weight percent)-Yue 99% weight, and more particularly, the The compounds of this invention of about 0.10% weight-50% weight, all weight percents are all based on the total weight of composition.
Adopt known standard, comprise the response of age, weight and individual patient, those of ordinary skill in the art can determine treatment significant quantity of the invention process, and is illustrated in the context of the disease of being treated or being prevented.
Purposes:
We have found that compound of the present invention shows as medicine, especially as the activity of the conditioning agent of metabotropic glutamate receptor.More particularly, compound of the present invention shows the activity as the synergistic agent of mGluR2 acceptor.Therefore, this compounds and the medicinal compositions that contain them are being treated, and are being useful aspect sick of the L-glutamic acid dysfunction related neural of treatment animal and the psychiatric disorders especially.
Be suitable for comprising with the neurological and the psychiatric disorders of compounds for treating disclosed herein, but be not limited to following disease, for example, heart bypass operation and transplant after cause brain damaged, apoplexy, cerebral ischemia, spinal cord injuries receptor, wound, perinatal hypoxia, heart stopping collecting, hypoglycemic neuronal damage, dull-witted (comprising the dementia that AIDS brings out), presenile dementia, huntington's chorea, amyotrophic lateral sclerosis, ocular injury, retinopathy, cognitive disorder, spontaneous and drug-induced Parkinson's disease, muscle spasm and comprise with the muscle spasm diseases associated is trembled, epilepsy, faint from fear, the brain of epileptic state that is secondary to prolongation is damaged, migraine (comprising the migraine headache), the urinary incontinence, the material tolerance, material is given up disease and (is comprised that material is opium for example, Nicotine, tobacco product, alcohol, benzodiazepine
Cocaine, tranquilizer, soporific etc.), psychosis, schizophrenia, anxiety disorder (comprises generalized anxiety disorder, paranoid fears, social phobia, obsession and post-traumatic stress disorder (PTSD)), mood disorder (comprises dysthymia disorders, mania, attention-deficient), circadian rhythm obstacle (comprising jet lag and shift work syndrome), trigeminal neuralgia, hearing disability, tinnitus, the eyes macular degeneration, vomiting, cerebral edema, pain (comprises acute and the chronic pain state, have an intense pain, refractory pain, neuropathic pain, pain after inflammatory pain and the wound), tardive dyskinesia, somnopathy (comprising hypnolepsy), attention-deficient/hyperfunction obstacle and behavior disorder.
Therefore, the invention provides according to the compound of formula I or its pharmacy acceptable salt or solvate and be used for the treatment of purposes in the medicine of above-mentioned any illness in preparation.
In addition, the invention provides the method that treatment suffers from the curee of above-mentioned any illness, thereby need compound or its pharmacy acceptable salt or the solvate according to formula I of patient's significant quantity of treatment like this.As indicated above such, the present invention also provides formula I compound or its pharmacy acceptable salt or the purposes of solvate in treatment.
In the application's context, term " treatment " also comprises " prevention " is unless there is opposite explanation in addition.Term " treatment " and " remedially " should be explained accordingly.Term in the context of the invention " treatment " further comprises the The compounds of this invention that gives significant quantity, alleviating acute or chronic already present morbid state, or alleviates the recurrence disease.This definition also is included as the prophylactic treatment of prevention of recurrence disease and to the continued treatment of chronic disease.
Warm-blooded animal, for example in people's the therepic use, can be by any approach, comprise in per os, intramuscular, subcutaneous, local, the nose, in the intraperitoneal, intrathoracic, intravenously, epidural, sheath, Intraventricular, with by being expelled in the joint, give compound of the present invention with the form of conventional medicinal compositions.In particular of the present invention, route of administration is per os, intravenously or intramuscular.
Dosage will depend on route of administration, severity of disease, age and patient's body weight and each dosage of definite particular patient and the common other factors of considering of attending doctor of dosage level.
Such as mentioned above, can be to be suitable for oral form, for example, provide or transmit compound as herein described with the form of tablet, lozenge, hard and soft capsule, aqueous solution agent, oily solution agent, emulsion and suspensoid.As selection, described compound can be configured to topical, for example, and as creme, ointment, gelifying agent, sprays or aqueous solution agent, oily solution agent, emulsion or suspensoid.Also can provide to be the form that is suitable for nose administration, for example, as the compound as herein described of nasal spray, nasal drop or dried powder.Can suppository form give described compound to vagina or rectum.Also can be through parenteral, for example, give compound as herein described through intravenously, intravesical (intravesicular), subcutaneous or intramuscularly or transfusion.Can give described compound through sucking (for example, as finely divided powder).Also can give described compound through transdermal or hypogloeeis.
Except they the purposes aspect the medicine, the formula I compound or its salt also exploitation of pilot system in vitro and in vivo and stdn aspect is used in the effect of estimating the inhibitor of mGluR related activity as the laboratory animal of the part of novel treatment research as pharmacological tool.This class animal comprises, for example, and cat, dog, rabbit, monkey, rat and mouse.The preparation method:
Prepare in the limit of power that is chosen in those skilled in the art of ad hoc approach of given compound.Therefore, certain structural features and/or substituent selection may influence selects a kind of method, and does not select another kind of method.
Under these total guilding principles, can adopt following method to prepare the exemplary subgroup of The compounds of this invention.Except as otherwise noted, the definition of given those variablees of following flow process and the variable described in the method and following formula I is identical.
In one approach, for example, at formula R
1(CR
8CR
9)
nNH
2The existence of amine under, make the cyclisation of formula Ia compound:
Obtain formula Ib compound:
Formula Ib compound again with contain R
5Suitable reagent cross-coupling, obtain compound according to formula Ic:
In an embodiment of present method, synthetic 5-replaces-7-methyl isoindolone as shown in following flow process 1.Under the Sandmeyer reaction conditions, 4-bromo-2, the 6-xylidine is converted into corresponding nitrile.Nitrile progressively is hydrolyzed to acid again.Can obtain acid amides by alkaline hydrolysis.Acid amides by nitrosyl-sulfuric acid diazotization and hydrolysis, obtains phenylformic acid again, is methyl esters with standard conditions with its protection subsequently.As radical initiator, the methyl of benzyl is by N-bromosuccinimide list bromination with benzoyl peroxide.Alkali for example salt of wormwood in the presence of, be isoindolone with suitable amine with this resultant intermediate cyclisation.Finally, adopt typical B uchwald, Suzuki or Stille cross-coupling reaction condition and reagent, with substituent R
5Be incorporated on the C5 of isoindolone.
Flow process 1:
(a) NaCN, CuCN, HCl; (b) NaOH; (c) nitrosyl-sulfuric acid; (d) MeI, K
2CO
3(e) NBS, (PhCO
2)
2(f) R1CH
2NH
2, K
2CO
3(g) R5H, BINAP, PdCl
2(dppf), NaOtBu or R5B (OH)
2, PdCl
2(dppf), K
2CO
3Or R5SnBu
3, Pd (PPh
3)
4
In another embodiment of this method, synthetic 5-replacement-7-chloro isoindolone as shown in following flow process 2.With N-chlorosuccinimide and palladium catalyst at the ortho position of acid chlorination 4-bromo-2-tolyl acid.To be similar to the above (flow process 1) method, this acid is esterified again, bromination and cyclisation, obtains the isoindolone intermediate.Introduce substituent R similarly
5
Flow process 2:
(a) NCS, Pd (OAc)
2(b) MeI, K
2CO
3(c) NBS, (PhCO
2)
2(d) R1CH
2NH
2, K
2CO
3(e) R5H, BINAP, PdCl
2(dppf), NaOtBu or R5B (OH)
2, PdCl
2(dppf), K
2CO
3Or R5SnBu
3, Pd (PPh
3)
4
In another embodiment of present method, can as shown in following flow process 3, prepare the isoindolone that on C5, is replaced by acid amides.Therefore, in the presence of palladium catalyst, the 5-bromo isoindolone that will suitably replace with zinc cyanide is converted into corresponding nitrile.Under alkaline condition,, obtain phenylformic acid again, make itself and various amine coupling with method well known in the art again, obtain final compound the nitrile hydrolysis.
Flow process 3:
(a)Zn(CN)
2，Pd(PPh
3)
4；(b)NaOH；(c)RR′NH，EDCI
Additive on the variable of preceding method and its appears among subsequently the embodiment.Therefore, those of ordinary skill in the art can be appreciated that, can according to or adopt one or more methods disclosed herein, preparation The compounds of this invention.
By being intended to describe in detail the following example of several embodiments of the present invention, further specify the present invention.These embodiment neither plan, the scope that they can not be construed as limiting the invention.Should be clear and definite, the concrete narration of the available this paper of being different from such realizes the present invention.According to described herein, a large amount of modification of the present invention and variation are possible, thereby they all within the scope of the invention
Universal method:
All raw materials can obtain or narration more arranged in the literature through commercial approach.
Except as otherwise noted, in deuterate chloroform, adopt TMS or residual solvent signal in contrast as solvent,
1H and
13C NMR spectrum is recorded in respectively and exists
1On Bruker 300, the Bruker DPX400 or Varian+400 spectrometer that 300,400 and the 400MHz of H NMR moves down.All chemical shifts of report represent with the ppm on the δ scale, the trickle multiplicity of signal also appear in the record (s: unimodal, br s: wide unimodal, d: bimodal, t: three peaks, q: four peaks, m: multiplet).
Separate according to the liquid chromatography of the on-line analysis of mass spectrometric detection and to be embedded on the Waters LCMS that forms by Alliance 2795 (LC) and the single quadrupole mass spectrometer of ZQ.This mass spectrograph is equipped with just and/or the electric spray ion source of negative ion mode operation.Ionspray voltage is ± 3kV that during sweep time, mass spectrograph is scanned from m/z 100 to 700 at 0.8s.Coupled columns, utilization X-TerraMS, Waters, C8,2.1 * 50mm, 3.5mm, linear gradient is in the 10mM ammonium acetate (aqueous solution) or the 5%-100% acetonitrile among the 0.1%TFA (aqueous solution).
The preparation reverse-phase chromatography moves on the automatic preparation HPLC of Gilson of band diode-array detector, adopts XTerra MS C8,19 * 300mm, and 7mm is as post.
Adopt TC Research 7924T chromatotron through the purifying of chromatotron through be coated with 1,2 or the rotation silica gel/gypsum (Merck, the 60PF-254 of band calcium sulfate) of 4mm coating layer sheet glass on carry out.
Also adopt Chem Elut column extractor (Varian, Cat #1219-8002), Mega BE-SI (Bond Elut Silica) SPE post (Varian, Cat #12256018; 12256026; 12256034) or by the filling silica gel glass column in the flash chromatography method, purified product.
[0001] be 2450MHz produce carry out in the Smith synthesizer single-mode microwave office of continuous gamma radiation microwave heating (individual's chemistry (Personal Chemistry) AB, Uppsala, Sweden).
Can adopt the pharmacological property of analyzing The compounds of this invention at the standard test of functionally active.For example, the example of glutamate receptor test such as Aramori etc., 1992, Neuron, 8:757; Tanabe etc., 1992, Neuron, 8:169; Miller etc., 1995, J.Neuroscience, 15:6103; Balazs, etc., 1997, J.Neurochemistry, 1997, described in the 69:151 like that, for known in the art.Method described in these publications is incorporated herein by reference.Expediently, can be by [the Ca in the cell of measuring intracellular Ca2+, expression mGluR2
2+] the test of moving, the research The compounds of this invention.
With the board-like reader of fluorescence imaging (FLIPR) analytical method, move detection mGluR2 allosteric activator through calcium.Employing is fused to and mixes the chimeric protein G of dwelling
α qj5, express clone HEK 293 clones that the chimeric mGluR2/CaR comprise people mGluR2 extracellular domain and membrane-spanning domain and people's calcium recipient cell intracellular domain constitutes thing.This constitutes thing by agonist or allosteric activator activation, causes stimulating the PLC approach and Ca in the follow-up cell of FLIPR analysis to measure
2+Move.In analysis preceding 24 hours, the cell trypsinize also was tiled among DMEM black limit, clear bottom, collagen I coating, in the 96-well culture plate with 100,000 cells/well.In 37 ℃, 5%CO
2Cultivate this culture plate down.Under the room temperature, with 6 μ M Fluo-3 acetoxyl methyl esters (molecular probe, Eugene Oregon) load cells 60 minutes.Containing 126mMNaCl, 5mM KCl, the 1mM MgCl that is supplemented with 1.0mg/ml D-glucose and 1.0mg/ml BSA flow point IV (pH 7.4)
2, 1mM CaCl
2, 20mM Hepes, 0.06 μ MDCG-IV (II group mGluR selective agonist) buffered soln in, carry out all tests.
Adopt 0.8W laser aid and 0.4 second CCD camera shutter speed to carry out the FLIPR experiment.Extracellular fluo-3 is by flush away, and cell is maintained in the 160 μ L damping fluids and is tiled among the FLIPR.After 10 seconds, adding test compounds (0.01 μ M-30 μ M, duplicate) with FLIPR record baseline fluorescence reading.After 75 seconds, note down fluorescent signal again, add DCG-IV (0.2M) for the second time this moment, after 65 seconds, the record fluorescent signal.Fluorescent signal is measured as the peak heights of the response during sample.Calculate EC with Assay Explorer analytical data with four parameter logarithmic equations
50And E
MaxValue (with respect to maximum DCG-IV effect).
A[
35S]-GTP γ S is used to the receptor activation from function check mGluR2 in conjunction with test.With the film of the Chinese hamster ovary celI that is prepared in stably express people mGluR2, adopt [
35S]-GTP γ S is in conjunction with test, and the allosteric activator of mensuration compound is to the activity of people mGluR2 acceptor.This test is incorporated into the protein-coupled acceptor of G-based on agonist, to stimulate the principle of the proteic GDP-GTP exchange of G-.Since [
35S]-GTP γ S is the GTP analogue of non-hydrolysable, therefore, it can be used to provide the index of GDP-GTP exchange and receptor activation.Therefore, GTP γ S provides the quantitative assay of receptor activation in conjunction with test.
Film is by being prepared by the Chinese hamster ovary celI of people mGluR2 stable transfection.Under the room temperature, before adding 1 μ M L-glutamic acid, use test compounds (3nM-300 μ M) culture membrane (30 μ g albumen) 15 minutes, and containing 30 μ M GDP and 0.1nM[in 30 ℃
35S]-the 500 μ L of GTP γ S (1250Ci/mmol) test damping fluid (20mM HEPES, 100mM NaCl, 10mMMgCl
2) the middle cultivation 30 minutes.In 2mL polypropylene 96-well culture plate, carry out reaction repeated three times.With Packard 96-hole collector and Unifilter-96, GF/B strainer microtest plate, through the vacuum filtration termination reaction.With the ice-cold lavation buffer solution of 4 * 1.5mL (10mM sodium phosphate buffer, pH 7.4) washing filter culture plate.The device for drying and filtering culture plate adds 35 μ L scintillating liquids (Microscint 20) to each hole.By calculating culture plate, determine the amount of radioactivity boundary with Packard TopCount.With GraphPad Prism analytical data, calculate EC with non-linear regression
50And E
MaxValue (with respect to the effect of maximum valley propylhomoserin).
In general, in test as herein described, at concentration (or EC
50During value) less than 10 μ M, compound of the present invention is activated.
Illustrative methods:
Compound 1:2-[4-(4-fluoro-phenoxy group)-benzyl]-2,3-dihydro-isoindole-1-ketone
Under 100 ℃, stir on the limit, the limit add 2-bromomethyl-methyl benzoate in the hot toluene (5mL) (0.108g, 0.5mmol), 4-(4-fluoro-phenoxy group)-benzylamine (0.115g, 0.5mmol) and K
2CO
3(0.235g, mixture 2h 1.7mmol).The silica gel column chromatography of 30% ethyl acetate in aftertreatment and the employing hexane obtains 2-[4-(4-fluoro-phenoxy group)-benzyl]-2,3-dihydro-isoindole-1-ketone (0.100g, 60%).
1H?NMR(300MHz，CDCl
3)：δ(ppm)4.29(s，2H)，4.78(s，2H)6.83-7.56(m，11H)，7.89(d，1H).GC-MS：m/z?333(M)
+.
Compound 2:2-[4-(4-three fluoro methyl-phenoxy groups)-benzyl]-2,3-dihydro-isoindole-1-ketone
Under 100 ℃, add while stirring 2-bromomethyl-methyl benzoate in the hot toluene (5mL) (0.115g, 0.5mmol), 4-(4-trifluoromethyl-phenoxy group)-benzylamine (0.133g, 0.5mmol) and K
2CO
3(0.235g, mixture 2h 1.7mmol).The silica gel column chromatography of 30% ethyl acetate in aftertreatment and the employing hexane obtains 2-[4-(4-trifluoromethyl-phenoxy group)-benzyl]-2,3-dihydro-isoindole-1-ketone (0.116g, 60%).
1H?NMR(300MHz，CDCl
3)：δ(ppm)4.32(s，2H)，4.81(s，2H)7.01-7.56(m，1IH)，7.91(d，IH).GC-MS：m/z383(M)
+.
Compound 3:-{3-[4-(4-fluoro-phenoxy group)-phenyl]-propyl group }-7-iodo-2,3-dihydro-isoindole-1-ketone
Under 100 ℃, add while stirring 2-bromomethyl-6-iodo-methyl benzoate in the hot toluene (5mL) (0.245g, 0.7mmol), 3-[4-(4-fluoro-phenoxy group) phenyl]-propylamine (0.193g, 0.8mmol) and K
2CO
3(0.207g, mixture 2h 1.5mmol).The silica gel column chromatography of 30% ethyl acetate in aftertreatment and the employing hexane obtains 2-{3-[4-(4-fluoro-phenoxy group)-phenyl]-propyl group }-7-iodo-2,3-dihydro-isoindole-1-ketone (0.086g, 25%).
1H?NMR(300MHz，CDCl
3)：δ(ppm)2.01(m，2H)，2.65(t，2H)，3.67(t，2H)，4.26(s，2H)，6.84-7.42(m，10H)，7.90(d，IH)。GC-MS：m/z?487(M)
+.
Compound 4:7-iodo-2-[3-(2-methoxyl group-phenoxy group)-benzyl]-2,3-dihydro-isoindole-1-ketone
Under 100 ℃, add while stirring 2-bromomethyl-6-iodo-methyl benzoate in the hot toluene (5mL) (0.178g, 0.5mmol), 3-(2-methoxyl group-phenoxy group)-benzylamine (0.160g, 0.6mmol) and K
2CO
3(0.138g, mixture 2h 1.0mmol).The silica gel column chromatography of 30% ethyl acetate in aftertreatment and the employing hexane obtains 7-iodo-2-[3-(2-methoxyl group-phenoxy group)-benzyl]-2,3-dihydro-isoindole-1-ketone (0.056g, 24%).
1H?NMR(300MHz，CDCl
3)：δ(ppm)3.82(s，3H)，4.16(s，2H)，4.74(s，2H)，6.84-7.40(m，10H)，7.92(d，1H).GC-MS：m/z?471(M)
+.
By being similar to those methods described in compound 1,2,3 and 4, preparation the following example compound:
Embodiment 1:5-bromo-2-[4-(2-fluorinated phenoxy) benzyl]-7-methyl-2,3-dihydro-isoindole-1-ketone
0.80g, 42%, yellow oil.7.37(d，2H)，7.27(d，2H)，7.02-7.22(m，4H)，6.95(d，2H)，4.73(s，2H)，4.21(s，2H)，2.74(s，3H).
Embodiment 2:5-bromo-2-[4-(3-fluorinated phenoxy) benzyl]-7-methyl-2,3-dihydro-isoindole-1-ketone
0.58g, 26%, yellow solid.7.38(d，2H)，7.27-7.33(m，3H)，7.02(d，2H)，6.75-6.85(m，2H)，6.66-6.72(m，1H)，4.76(s，2H)，4.24(s，2H)，2.75(s，3H).
Embodiment 3:5-bromo-2-[4-(4-fluorinated phenoxy) benzyl]-7-methyl-2,3-dihydro-isoindole-1-ketone
0.38g, 34%, yellow oil.7.37(d，2H)，7.27(d，2H)，6.90-7.10(m，6H)，4.73(s，2H)，4.22(s，2H)，2.75(s，3H).
Embodiment 4:5-bromo-7-methyl-2-[4-(pyridine-2-base oxygen base) benzyl]-2,3-dihydro-isoindole-1-ketone
0.42g, 40%, yellow oil.8.17-8.22(m，1H)，7.67-7.75(m，1H)，7.33-7.39(m，4H)，7.13(d，2H)，7.00-7.05(m，1H)，6.93(d，2H)，4.77(s，2H)，4.25(s，2H)，2.75(s，3H).
Embodiment 5:5-bromo-7-methyl-2-[4-(pyridin-3-yl oxygen base) benzyl]-2,3-dihydro-isoindole-1-ketone
0.19g, 9%, orange solids.8.37-8.42(m，2H)，7.38(d，2H)，7.28-7.33(m，4H)，7.01(d，2H)，4.76(s，2H)，4.24(s，2H)，2.75(s，3H).
Embodiment 6:2-[4-(2-fluoro-phenoxy group)-benzyl]-7-methyl-5-pyridine-2-base-2,3-dihydro-isoindole-1-ketone
64mg, 64%, light yellow solid.8.70-8.75(m，1H)，7.77-7.85(m，4H)，7.27-7.32(m，3H)，7.02-7.23(m，4H)，6.97(d，2H)，4.79(s，2H)，4.31(s，2H)，2.85(s，3H).
Embodiment 7:2-[4-(2-fluoro-phenoxy group)-benzyl]-7-methyl-5-pyridin-3-yl-2,3-dihydro-isoindole-1-ketone
38mg, 38%, light yellow oil.8.86(d，1H)，8.65(dd，1H)，7.85-7.92(m，1H)，7.38-7.41(m，3H)，7.30(d，2H)，7.02-7.23(m，4H)，6.96(d，2H)，4.79(s，2H)，4.32(s，2H)，2.85(s，3H).
Embodiment 8:2-[4-(2-fluoro-phenoxy group)-benzyl]-7-methyl-5-pyrazine-2-base-2,3-dihydro-isoindole-1-ketone
24mg, 24%, shallow white solid.9.07(d，1H)，8.68(dd，1H)，8.58(d，1H)，7.87(s，2H)，7.29(d，2H)，7.02-7.23(m，4H)，6.96(d，2H)，4.79(s，2H)，4.34(s，2H)，2.87(s，3H).
Embodiment 9:7-methyl-5-pyrazine-2-base-2-[4-(pyridine-2-base oxygen base)-benzyl]-2,3-dihydro-isoindole-1-ketone
22mg, 22%, shallow white solid.9.08(d，1H)，8.67-8.69(m，1H)
58.58(d，1H)，8.15-8.25(m，1H)，7.87(s，2H)，7.65-7.75(m，1H)，7.39(d，2H)，7.14(d，2H)，6.98-7.05(m，1H)，6.93(d，1H)，4.83(s，2H)，4.38(s，2H)，2.88(s，3H).
Embodiment 10:2-[4-(4-fluoro-phenoxy group)-benzyl]-7-methyl-5-pyridine-2-base-2,3-dihydro-isoindole-1-ketone
43mg, 51%, yellow oil.8.72-8.74(m，1H)，7.77-7.86(m，4H)，7.28-7.32(m，3H)，6.80-7.04(m，6H)，4.78(s，2H)，4.32(s，2H)，2.86(s，3H).
Embodiment 11:2-[4-(4-fluoro-phenoxy group)-benzyl]-7-methyl-5-pyridin-3-yl-2,3-dihydro-isoindole-1-ketone
22mg, 25%, yellow oil.8.86(d，1H)，8.63-8.66(m，1H)，7.85-7.95(m，1H)，7.40-7.43(m，3H)，7.30(d，2H)，6.90-7.05(m，6H)，4.79(s，2H)，4.33(s，2H)，2.85(s，3H).
Embodiment 12:2-[4-(4-fluoro-phenoxy group)-benzyl]-7-methyl-5-pyrazine-2-base-2,3-dihydro-isoindole-1-ketone
21mg, 25%, light yellow solid.9.07(d，1H)，8.67-8.69(m，1H)
38.58(d，1H)，7.87(s，2H)，7.31(d，2H)，6.90-7.08(m，6H)，4.79(s，2H)，4.34(s，2H)，2.87(s，3H).
Embodiment 13:2-[4-(3-fluoro-phenoxy group)-benzyl]-7-methyl-5-pyridine-2-base-2,3-dihydro-isoindole-1-ketone
41mg, 41%, water white oil.8.70-8.75(m，1H)，7.75-7.88(m，4H)，7.25-7.37(m，4H)，7.03(d，2H)，6.75-6.85(m，2H)，6.65-6.73(m，1H)，4.81(s，2H)，4.14(s，2H)，2.86(s，3H).
Embodiment 14:2-[4-(3-fluoro-phenoxy group)-benzyl]-7-methyl-5-pyrazine-2-base-2,3-dihydro-isoindole-1-ketone
27mg, 27%, shallow white solid.9.08(d，1H)，8.67-8.69(m，1H)，8.58(d，1H)，7.87-7.89(m，2H)，7.35(d，2H)，7.27-7.29(m，1H)，7.03(d，2H)，6.75-6.83(m，2H)，6.68-6.72(m，1H)，4.81(s，2H)，4.36(s，2H)，2.88(s，3H).
Embodiment 15:2-[4-(2-fluoro-phenoxy group)-benzyl]-7-methyl-5-thiazole-2-base-2,3-dihydro-isoindole-1-ketone
23mg, 26%, yellow oil.7.92(d，1H)，7.84(s，1H)，7.82(s，1H)
5?7.41(d，1H)，7.30(d，2H)，7.03-7.25(m，4H)，6.96(d，2H)，4.77(s，2H)，4.30(s，2H)，2.84(s，3H)。
Claims (27)
1. according to compound or its pharmacy acceptable salt, hydrate, solvate, optical isomer or its combination of formula I:
Wherein:
R
1Be to contain the first ring of the one or more heteroatomic 3-7 that independently is selected from N, O and S, wherein said ring is replaced by one or more B;
R
2And R
3Independently be selected from H and C
1-6-alkyl;
R
4Be H and R
6Be selected from H, hydroxyl, F, Cl, Br, I, nitro, cyano group, C
1-6-alkyl and OC
1-6Alkyl;
R
5Be selected from H, F, Cl, Br, I, nitro, CN, C
1-6-alkyl, OC
0-6-alkyl, C
1-6-haloalkyl, OC
1-6-haloalkyl, C
2-6-alkenyl, OC
2-6-alkenyl, C
2-6-alkynyl, OC
2-6-alkynyl, C
3-8-cycloalkyl, C
1-6-alkyl-C
3-8-cycloalkyl, OC
0-6-alkyl-C
3-8-cycloalkyl, aryl, C
1-6-alkylaryl, C
1-6-miscellaneous alkyl aryl, OC
1-6-alkylaryl, OC
1-6-miscellaneous alkyl aryl, C
1-6-alkyl heterocycle alkyl, O Heterocyclylalkyl, OC
1-6-alkyl heterocycle alkyl, C (O) H, (CO) R
10, O (CO) R
10, O (CO) OR
10, C (O) OR
10, O (CN) OR
10, C
1-6-alkyl OR
10, OC
2-6-alkyl OR
10, C
1-6-alkyl (CO) R
10, OC
1-6-alkyl (CO) R
10, C
0-6-alkyl CO
2R
10, C
1-6-alkyl cyano group, OC
2-6-alkyl cyano group, C
0-6-alkyl NR
10R
11, OC
2-6-alkyl NR
10R
11, C
1-6-alkyl (CO) NR
10R
11, OC
1-6-alkyl (CO) NR
10R
11, C
0-6-alkyl NR
10(CO) R
11, OC
2-6-alkyl NR
10(CO) R
11, C
0-6-alkyl NR
10(CO) NR
10R
11, C
0-6-alkyl SR
10, OC
2-6-alkyl SR
10, C
0-6-alkyl (SO) R
10, OC
2-6-alkyl (SO) R
10, C
0-6-alkyl SO
2R
10, OC
2-6-alkyl SO
2R
10, C
0-6-alkyl (SO
2) NR
10R
11, OC
2-6-alkyl (SO
2) NR
10R
11, C
0-6-alkyl NR
10(SO
2) R
11, OC
2-6-alkyl NR
10(SO
2) R
11, C
0-6-alkyl NR
10(SO
2) NR
10R
11, OC
2-6-alkyl NR
10(SO
2) NR
10R
11, (CO) NR
10R
11, O (CO) NR
10R
11, NR
10OR
11, C
0-6-alkyl NR
10(CO) OR
11, OC
2-6-alkyl NR
10(CO) OR
11, SO
3R
10With can contain the one or more heteroatomic 5-7 unit ring that independently is selected from N, O and S, wherein R
5Can be replaced by one or more A and wherein any loop section optional with can contain the one or more heteroatomic 5-7 unit that independently is selected from C, N, O and S and encircle and condense;
R
7Be selected from H, F, Cl, Br, I, nitro, cyano group, OC
1-4-alkyl and C
1-6-alkyl;
R
8And R
9Independently be selected from H, F, Cl, Br, I, nitro, cyano group, C
1-6-alkyl, C
1-6-haloalkyl, OC
1-6Alkyl, OC
1-6-haloalkyl, C
2-6-alkenyl, OC
2-6-alkenyl, C
2-6-alkynyl and OC
2-6-alkynyl, perhaps, wherein n is greater than 1, the two or more R on the adjacent carbons
8And/or R
9Can not exist, form alkenyl or alkynyl part;
R
10And R
11Independently be selected from H, hydroxyl, oxo, F, Cl, Br, I, nitro, cyano group, C
1-6-alkyl, C
1-6-haloalkyl, OC
1-6Alkyl, OC
1-6-haloalkyl, C
2-6-alkenyl, OC
2-6-alkenyl, C
2-6-alkynyl, OC
2-6-alkynyl, C
3-8-cycloalkyl, C
1-6-alkyl-C
3-8-cycloalkyl, OC
0-6-alkyl-C
3-8-cycloalkyl, aryl, C
1-6-alkylaryl, OC
0-6-alkylaryl, C
0-6-alkyl-Heterocyclylalkyl, OC
1-6-alkyl-Heterocyclylalkyl, heteroaryl and C
1-6Miscellaneous alkyl aryl, wherein any loop section is chosen wantonly and can be contained first ring of the one or more heteroatomic 5-7 that independently is selected from C, N, O and S and condenses and the optional substituting group replacement that is selected from alkyl, halogeno-group, hydroxyl, O alkyl, haloalkyl and O haloalkyl of any loop section;
A is selected from H, hydroxyl, F, Cl, Br, I, nitro, cyano group, oxo, C
1-6-alkyl, C
1-6-haloalkyl, OC
1-6Alkyl, OC
1-6-haloalkyl, C
2-6-alkenyl, OC
2-6-alkenyl, C
2-6-alkynyl, OC
2-6-alkynyl, C
3-8-cycloalkyl, C
1-6-alkyl-C
3-8-cycloalkyl, OC
0-6-alkyl-C
3-8-cycloalkyl, aryl, C
1-6-alkylaryl, OC
0-6-alkylaryl, C
1-6-alkyl-heterocyclic radical, C
1-6-alkyl-Heterocyclylalkyl, OC
0-6-alkyl-Heterocyclylalkyl, (CO) R
10, O (CO) R
10, O (CO) OR
10, O (CNR
10) OR
11, C
1-6-alkyl OR
10, OC
2-6-alkyl OR
10, C
1-6-alkyl (CO) R
10, OC
1-6-alkyl (CO) R
10, C
0-6-alkyl CO
2R
10, OC
1-6-alkyl CO
2R
10, C
1-6-alkyl cyano group, OC
2-6-alkyl cyano group, C
0-6-alkyl NR
10R
11, OC
2-6-alkyl NR
10R
11, C
0-6-alkyl (CO) NR
10R
11, OC
1-6-alkyl (CO) NR
10R
11, C
0-6-alkyl NR
10(CO) R
11, OC
2-6-alkyl NR
10(CO) R
11, C
0-6-alkyl NR
10(CO) NR
10R
11, C
0-6-alkyl SR
10, OC
2-6-alkyl SR
10, C
0-6-alkyl (SO) R
10, OC
2-6-alkyl (SO) R
10, C
1-6-alkyl SO
2R
10, OC
2-6-alkyl SO
2R
10, C
0-6-alkyl (SO
2) NR
10R
11, OC
2-6-alkyl (SO
2) NR
10R
11, C
0-6-alkyl NR
10(SO
2) R
11, OC
2-6-alkyl NR
10(SO
2) R
11, C
0-6-alkyl NR
10(SO
2) NR
10R
11, OC
2-6-alkyl NR
10(SO
2) NR
10R
11, (CO) NR
10R
11, O (CO) NR
10R
11, NR
10OR
11, C
0-6-alkyl NR
10(CO) OR
11, OC
2-6-alkyl NR
10(CO) OR
11, SO
3R
10With can contain the one or more heteroatomic 5-7 unit ring that independently is selected from N, O and S, wherein said 5-7 unit ring is optional by one or more R
10And R
11Replace;
B is selected from C
3-8-cycloalkyl, C
1-6-alkyl-C
3-8-cycloalkyl, OC
0-6-alkyl-C
3-8-cycloalkyl, C
0-6-alkylaryl, OC
0-6-alkylaryl, C
1-6-alkyl-Heterocyclylalkyl, C
1-6-alkyl-Heterocyclylalkyl, OC
0-6-alkyl-Heterocyclylalkyl, C
0-6-alkyl-heteroaryl and OC
0-6-alkyl-heteroaryl, wherein any loop section is selected from halogeno-group, alkyl, haloalkyl, hydroxyl, alkoxyl group, oxo, COR, CO
2R, SO
2At least one substituting group of R and CN replaces;
With
N is 1;
Prerequisite is that described compound is not:
2-[4-(4-fluoro-phenoxy group)-benzyl]-2,3-dihydro-isoindole-1-ketone;
2-[4-(4-trifluoromethyl-phenoxy group)-benzyl]-2,3-dihydro-isoindole-1-ketone;
2-{3-[4-(4-fluoro-phenoxy group)-phenyl]-propyl group }-7-iodo-2,3-dihydro-isoindole-1-ketone, or
7-iodo-2-[3-(2-methoxyl group-phenoxy group)-benzyl]-2,3-dihydro-isoindole-1-ketone.
2. the compound of claim 1 or its pharmacy acceptable salt, hydrate, solvate, optical isomer or its combination, wherein:
R
1Be phenyl, wherein said phenyl is replaced by one or more B;
R
2And R
3Independently be selected from H, C
1-6-alkyl, C
2-6-alkenyl, C
2-6-alkynyl, aryl, heteroaryl, Heterocyclylalkyl, C
3-8-cycloalkyl, C
1-6-alkyl-aryl, C
1-6-alkyl-heteroaryl, C
1-6-alkyl-Heterocyclylalkyl and C
1-6-alkyl-C
3-8-cycloalkyl, wherein R
2And R
3Can be replaced by one or more A;
R
4And R
6Independently be selected from H, hydroxyl, F, Cl, Br, I, nitro, cyano group, C
1-6-alkyl, C
1-6-haloalkyl, OC
1-6Alkyl, OC
1-6-haloalkyl, C
2-6-alkenyl, OC
2-6-alkenyl, C
2-6-alkynyl, OC
2-6-alkynyl, C
3-8-cycloalkyl, C
1-6-alkyl-C
3-8-cycloalkyl, OC
0-6-alkyl-C
3-8-cycloalkyl, aryl, C
1-6-alkylaryl, OC
0-6-alkylaryl, (CO) R
10, O (CO) R
10, O (CO) OR
10, C (O) OR
10, O (CNR
10) OR
11, C
1-6-alkyl OR
10, OC
2-6-alkyl OR
10, C
1-6-alkyl (CO) R
10, OC
1-6-alkyl (CO) R
10, C
0-6-alkyl CO
2R
10, OC
1-6-alkyl CO
2R
10, C
1-6-alkyl cyano group, OC
2-6-alkyl cyano group, C
0-6-alkyl NR
10R
11, OC
2-6-alkyl NR
10R
11, C
1-6-alkyl (CO) NR
10R
11, OC
1-6-alkyl (CO) NR
10R
11, C
0-6-alkyl NR
10(CO) R
11, OC
2-6-alkyl NR
10(CO) R
11, C
0-6-alkyl NR
10(CO) NR
10R
11, C
0-6-alkyl SR
10, OC
2-6-alkyl SR
10, C
0-6-alkyl (SO) R
10, OC
2-6-alkyl (SO) R
10, C
0-6-alkyl SO
2R
10, OC
2-6-alkyl SO
2R
10, C
0-6-alkyl (SO
2) NR
10R
11, OC
2-6-alkyl (SO
2) NR
10R
11, C
0-6-alkyl NR
10(SO
2) R
11, OC
2-6-alkyl NR
10(SO
2) R
11, C
0-6-alkyl NR
10(SO
2) NR
10R
11, OC
2-6-alkyl NR
10(SO
2) NR
10R
11, (CO) NR
10R
11, O (CO) NR
10R
11, NR
10OR
11, C
0-6-alkyl NR
10(CO) OR
11, OC
2-6-alkyl NR
10(CO) OR
11, SO
3R
10With can contain the one or more heteroatomic 5-7 unit ring that independently is selected from N, O and S, wherein R
4And R
6Can be replaced by one or more A and wherein any cycloalkyl or aryl optional with can contain the one or more heteroatomic 5-7 unit that independently is selected from C, N, O and S and encircle and condense;
R
5Be selected from H, F, Cl, Br, I, nitro, CN, C
1-6-alkyl, OC
0-6-alkyl, C
1-6-haloalkyl, OC
1-6-haloalkyl, C
2-6-alkenyl, OC
2-6-alkenyl, C
2-6-alkynyl, OC
2-6-alkynyl, C
3-8-cycloalkyl, C
1-6-alkyl-C
3-8-cycloalkyl, OC
0-6-alkyl-C
3-8-cycloalkyl, aryl, C
1-6-alkylaryl, C
1-6-miscellaneous alkyl aryl, OC
1-6-alkylaryl, OC
1-6-miscellaneous alkyl aryl, C
1-6-alkyl heterocycle alkyl, O Heterocyclylalkyl, OC
1-6-alkyl heterocycle alkyl, C (O) H, (CO) R
10, O (CO) R
10, O (CO) OR
10, C (O) OR
10, O (CN) OR
10, C
1-6-alkyl OR
10, OC
2-6-alkyl OR
10, C
1-6-alkyl (CO) R
10, OC
1-6-alkyl (CO) R
10, C
0-6-alkyl CO
2R
10, C
1-6-alkyl cyano group, OC
2-6-alkyl cyano group, C
0-6-alkyl NR
10R
11, OC
2-6-alkyl NR
10R
11, C
1-6-alkyl (CO) NR
10R
11, OC
1-6-alkyl (CO) NR
10R
11, C
0-6-alkyl NR
10(CO) R
11, OC
2-6-alkyl NR
10(CO) R
11, C
0-6-alkyl NR
10(CO) NR
10R
11, C
0-6-alkyl SR
10, OC
2-6-alkyl SR
10, C
0-6-alkyl (SO) R
10, OC
2-6-alkyl (SO) R
10, C
0-6-alkyl SO
2R
10, OC
2-6-alkyl SO
2R
10, C
0-6-alkyl (SO
2) NR
10R
11, OC
2-6-alkyl (SO
2) NR
10R
11, C
0-6-alkyl NR
10(SO
2) R
11, OC
2-6-alkyl NR
10(SO
2) R
11, C
0-6-alkyl NR
10(SO
2) NR
10R
11, OC
2-6-alkyl NR
10(SO
2) NR
10R
11, (CO) NR
10R
11, O (CO) NR
10R
11, NR
10OR
11, C
0-6-alkyl NR
10(CO) OR
11, OC
2-6-alkyl NR
10(CO) OR
11, SO
3R
10With can contain the one or more heteroatomic 5-7 unit ring that independently is selected from N, O and S, wherein R
5Can be replaced by one or more A and wherein any loop section optional with can contain the one or more heteroatomic 5-7 unit that independently is selected from C, N, O and S and encircle and condense;
R
7Be selected from H, F, Cl, Br, I, nitro, cyano group, OC
1-4-alkyl, C
1-6-alkyl, C
1-6-haloalkyl, OC
1-6-haloalkyl, C
2-6-alkenyl, OC
2-6-alkenyl, C
2-6-alkynyl, OC
2-6-alkynyl and C
3-8-cycloalkyl;
R
8And R
9All be H;
R
10And R
11Independently be selected from H, hydroxyl, oxo, F, Cl, Br, I, nitro, cyano group, C
1-6-alkyl, C
1-6-haloalkyl, OC
1-6Alkyl, OC
1-6-haloalkyl, C
2-6-alkenyl, OC
2-6-alkenyl, C
2-6-alkynyl, OC
2-6-alkynyl, C
3-8-cycloalkyl, C
1-6-alkyl-C
3-8-cycloalkyl, OC
0-6-alkyl-C
3-8-cycloalkyl, aryl, C
1-6-alkylaryl, OC
0-6-alkylaryl, C
0-6-alkyl-Heterocyclylalkyl, OC
1-6-alkyl-Heterocyclylalkyl, heteroaryl and C
1-6Miscellaneous alkyl aryl, wherein any loop section is chosen wantonly and can be contained first ring of the one or more heteroatomic 5-7 that independently is selected from C, N, O and S and condenses and the optional substituting group replacement that is selected from alkyl, halogeno-group, hydroxyl, O alkyl, haloalkyl and O haloalkyl of any loop section;
A is selected from H, hydroxyl, F, Cl, Br, I, nitro, cyano group, oxo, C
1-6-alkyl, C
1-6-haloalkyl, OC
1-6Alkyl, OC
1-6-haloalkyl, C
2-6-alkenyl, OC
2-6-alkenyl, C
2-6-alkynyl, OC
2-6-alkynyl, C
3-8-cycloalkyl, C
1-6-alkyl-C
3-8-cycloalkyl, OC
0-6-alkyl-C
3-8-cycloalkyl, aryl, C
1-6-alkylaryl, OC
0-6-alkylaryl, C
1-6-alkyl-heterocyclic radical, C
1-6-alkyl-Heterocyclylalkyl, OC
0-6-alkyl-Heterocyclylalkyl, (CO) R
10, O (CO) R
10, O (CO) OR
10, O (CNR
10) OR
11, C
1-6-alkyl OR
10, OC
2-6-alkyl OR
10, C
1-6-alkyl (CO) R
10, OC
1-6-alkyl (CO) R
10, C
0-6-alkyl CO
2R
10, OC
1-6-alkyl CO
2R
10, C
1-6-alkyl cyano group, OC
2-6-alkyl cyano group, C
0-6-alkyl NR
10R
11, OC
2-6-alkyl NR
10R
11, C
0-6-alkyl (CO) NR
10R
11, OC
1-6-alkyl (CO) NR
10R
11, C
0-6-alkyl NR
10(CO) R
11, OC
2-6-alkyl NR
10(CO) R
11, C
0-6-alkyl NR
10(CO) NR
10R
11, C
0-6-alkyl SR
10, OC
2-6-alkyl SR
10, C
0-6-alkyl (SO) R
10, OC
2-6-alkyl (SO) R
10, C
1-6-alkyl SO
2R
10, OC
2-6-alkyl SO
2R
10, C
0-6Alkyl (SO
2) NR
10R
11, OC
2-6Alkyl (SO
2) NR
10R
11, O
0-6Alkyl NR
10(SO
2) R
11, OC
2-6-alkyl NR
10(SO
2) R
11, C
0-6-alkyl NR
10(SO
2) NR
10R
11, OC
2-6-alkyl NR
10(SO
2) NR
10R
11, (CO) NR
10R
11, O (CO) NR
10R
11, NR
10OR
11, C
0-6-alkyl NR
10(CO) OR
11, OC
2-6-alkyl NR
10(CO) OR
11, SO
3R
10With can contain the one or more heteroatomic 5-7 unit ring that independently is selected from N, O and S, wherein said 5-7 unit ring is optional by one or more R
10And R
11Replace;
B is selected from C
0-6-alkylaryl and OC
0-6-alkylaryl, wherein any aryl moiety is selected from halogeno-group, alkyl, haloalkyl, hydroxyl, alkoxyl group, oxo, COR, CO
2R, SO
2At least one substituting group of R and CN replaces;
With
N is 1.
3. the compound of claim 1 or its pharmacy acceptable salt, hydrate, solvate, optical isomer or its combination, wherein:
R
1Be phenyl, wherein said phenyl is replaced by one or more B;
R
2And R
3Independently be selected from H and C
1-6-alkyl;
R
4Be H and R
6Be selected from H, hydroxyl, F, Cl, Br, I, nitro, cyano group, C
1-6-alkyl and OC
1-6Alkyl;
R
5Be selected from H, F, Cl, Br, I, maybe can contain the first ring of the one or more heteroatomic 5-7 that independently is selected from N, O and S;
R
7Be selected from H or C
1-6-alkyl;
R
8And R
9All be H;
B is OC
0-6At least one substituting group that-alkylaryl, wherein said aryl moiety are selected from halogeno-group, alkyl, haloalkyl and alkoxyl group replaces,
With
N is 1.
4. the compound of claim 1 or its pharmacy acceptable salt, hydrate, solvate, optical isomer or its combination, wherein:
N be 1,2 or 3 and when n greater than 1 the time, the two or more R on the adjacent carbons
8And R
9May not exist, so that form fractional saturation or complete undersaturated part.
5. the compound of claim 1 or its pharmacy acceptable salt, hydrate, solvate, optical isomer or its combination, wherein:
N is 1, and R
8And R
9Respectively be H.
6. the compound of claim 1 or its pharmacy acceptable salt, hydrate, solvate, optical isomer or its combination, wherein:
R
4And R
6Respectively be H.
7. the compound of claim 1 or its pharmacy acceptable salt, hydrate, solvate, optical isomer or its combination, wherein:
R
1Be to be selected from optional be selected from F, Cl, Br, I, OC
1-6-haloalkyl and OC
0-6Aryl, C that one or more A of-alkylaryl replace
3-8The 5-7 unit ring of-cycloalkyl, cycloalkenyl group and heterocyclic radical.
8. the compound of claim 1 or its pharmacy acceptable salt, hydrate, solvate, optical isomer or its combination, wherein:
R
1Be selected from phenyl, naphthyl, C
3-8-cycloalkyl, cycloalkenyl group, furyl, tetrahydrofuran base, thienyl, pyridyl, oxadiazole base, quinolyl, piperazinyl and THP trtrahydropyranyl.
9. the compound of claim 1 or its pharmacy acceptable salt, hydrate, solvate, optical isomer or its combination, wherein:
R
1Be optional be selected from F, Cl, Br, I, OC
1-6-haloalkyl and OC
0-6The phenyl that one or more A of-alkylaryl replace.
10. the compound of claim 9 or its pharmacy acceptable salt, hydrate, solvate, optical isomer or its combination, wherein:
R
2, R
3, R
4, R
6, R
8And R
9Respectively be H and n be 1 and
R
7Be selected from H, Cl, Br, I, C
1-6-alkyl and OC
1-4-alkyl.
11. the compound of claim 1 or its pharmacy acceptable salt, hydrate, solvate, optical isomer or its combination, wherein:
R
5Be selected from C
3-8-cycloalkyl, C
1-6-alkyl-C
3-8-cycloalkyl, OC
0-6-alkyl-C
3-8-cycloalkyl, aryl, C
1-6-alkylaryl, OC
1-6The one or more heteroatomic 5-7 unit that-alkylaryl and can containing independently is selected from N, O and S encircles;
R wherein
5Can be replaced by one or more A and any cycloalkyl or aryl optional with can contain the one or more heteroatomic 5-7 unit that independently is selected from C, N, O and S and encircle and condense.
12. the compound of claim 11 or its pharmacy acceptable salt, hydrate, solvate, optical isomer or its combination, wherein:
R
5Be selected from C
1-6The one or more heteroatomic 5-7 unit that-alkylaryl and can containing independently is selected from N, O and S encircles, wherein R
5Can be replaced by one or more A.
13. the compound of claim 12 or its pharmacy acceptable salt, hydrate, solvate, optical isomer or its combination, wherein:
R
5Be to contain the first ring of the one or more heteroatomic 5-7 that independently is selected from N, O and S, this ring is selected from C
1-6-alkyl-heterocyclic radical replaces with one or more A that can contain the first ring of one or more heteroatomic 5-7 that independently is selected from N, O and S.
14. the compound of claim 1 or its pharmacy acceptable salt, hydrate, solvate, optical isomer or its combination, wherein:
N is 1,2 or 3;
R
4, R
6, R
8And R
9Respectively be H;
R
1Be selected from optional be selected from F, Cl, Br, I, OC
1-6-haloalkyl and OC
0-6Aryl, C that one or more A of-alkylaryl replace
3-8-cycloalkyl, cycloalkenyl group and heterocyclic radical;
R
7Be selected from H, Cl, Br, I, C
1-6-alkyl and OC
1-4-alkyl,
With
R
5Be selected from C
3-8-cycloalkyl, C
1-6-alkyl-C
3-8-cycloalkyl, OC
0-6-alkyl-C
3-8-cycloalkyl, aryl, C
1-6-alkylaryl, OC
1-6The one or more heteroatomic 5-7 unit that-alkylaryl and can containing independently is selected from N, O and S encircles, wherein R
5Can be replaced by one or more A and wherein any loop section optional with can contain the one or more heteroatomic 5-7 unit that independently is selected from C, N, O and S and encircle and condense.
15. the compound of claim 1 or its pharmacy acceptable salt, hydrate, solvate, optical isomer or its combination, wherein:
N is 1,2 or 3;
R
4, R
6, R
8And R
9Respectively be H;
R
1Be selected from optional be selected from F, Cl, Br, I, OC
1-6-haloalkyl and OC
0-6Phenyl, naphthyl, C that one or more A of-alkylaryl replace
3-8-cycloalkyl, cycloalkenyl group, furyl, tetrahydrofuran base, thienyl, pyridyl, oxadiazole base, quinolyl, piperazinyl and THP trtrahydropyranyl; R
7Be selected from Cl, Br, I and-OCH
3, and R
5Be selected from C
1-6The one or more heteroatomic 5-7 unit that-alkylaryl and can containing independently is selected from N, O and S encircles, wherein R
5Can be replaced by one or more A.
16. the compound of claim 1 or its pharmacy acceptable salt, hydrate, solvate, optical isomer or its combination, wherein:
N is 1,2 or 3;
R
4, R
6, R
8And R
9Respectively be H;
R
1Be optional be selected from F, Cl, Br, I, OC
1-6-haloalkyl and OC
0-6The phenyl that one or more A of-alkylaryl replace; R
7Be selected from H, Cl, Br, I, C
1-6-alkyl and OC
1-4-alkyl, and R
5Be to contain the first ring of the one or more heteroatomic 5-7 that independently is selected from N, O and S, wherein this 5-7 unit ring is selected from C
1-6-alkyl-heterocyclic radical replaces with one or more A that can contain the first ring of one or more heteroatomic 5-7 that independently is selected from N, O and S.
17. the compound of claim 1 or its pharmacy acceptable salt, hydrate, solvate, optical isomer or its combination, wherein:
N is 1;
R
2, R
3, R
4, R
6, R
8And R
9Respectively be H;
R
1Be optional be selected from F, Cl, Br, I, OC
1-6-haloalkyl and OC
0-6The phenyl that one or more A of-alkylaryl replace; R
7Be selected from Cl, Br, I and-OCH
3, and R
5Be selected from C
1-6The one or more heteroatomic 5-7 unit that-alkylaryl and can containing independently is selected from N, O and S encircles, wherein R
5Can be replaced by one or more A.
18. the compound of claim 1, described compound is selected from:
5-bromo-2-[4-(2-fluorinated phenoxy) benzyl]-7-methyl-2,3-dihydro-isoindole-1-ketone;
5-bromo-2-[4-(3-fluorinated phenoxy) benzyl]-7-methyl-2,3-dihydro-isoindole-1-ketone;
5-bromo-2-[4-(4-fluorinated phenoxy) benzyl]-7-methyl-2,3-dihydro-isoindole-1-ketone;
5-bromo-7-methyl-2-[4-(pyridine-2-base oxygen base) benzyl]-2,3-dihydro-isoindole-1-ketone;
5-bromo-7-methyl-2-[4-(pyridin-3-yl oxygen base) benzyl]-2,3-dihydro-isoindole-1-ketone;
2-[4-(2-fluoro-phenoxy group)-benzyl]-7-methyl-5-pyridine-2-base-2,3-dihydro-isoindole-1-ketone;
2-[4-(2-fluoro-phenoxy group)-benzyl]-7-methyl-5-pyridin-3-yl-2,3-dihydro-isoindole-1-ketone;
2-[4-(2-fluoro-phenoxy group)-benzyl]-7-methyl-5-pyrazine-2-base-2,3-dihydro-isoindole-1-ketone;
7-methyl-5-pyrazine-2-base-2-[4-(pyridine-2-base oxygen base)-benzyl]-2,3-dihydro-isoindole-1-ketone;
2-[4-(4-fluoro-phenoxy group)-benzyl]-7-methyl-5-pyridine-2-base-2,3-dihydro-isoindole-1-ketone;
2-[4-(4-fluoro-phenoxy group)-benzyl]-7-methyl-5-pyridin-3-yl-2,3-dihydro-isoindole-1-ketone;
2-[4-(4-fluoro-phenoxy group)-benzyl]-7-methyl-5-pyrazine-2-base-2,3-dihydro-isoindole-1-ketone;
2-[4-(3-fluoro-phenoxy group)-benzyl]-7-methyl-5-pyridine-2-base-2,3-dihydro-isoindole-1-ketone;
2-[4-(3-fluoro-phenoxy group)-benzyl]-7-methyl-5-pyrazine-2-base-2,3-dihydro-isoindole-1-ketone and
2-[4-(2-fluoro-phenoxy group)-benzyl]-7-methyl-5-thiazole-2-base-2,3-dihydro-isoindole-1-ketone.
19. a medicinal compositions, it contains among the with good grounds claim 1-18 each compound and pharmaceutically acceptable carrier or vehicle.
20. one kind according to each compound among the claim 1-18, it is as medicine.
21. according among the claim 1-18 each compound preparation be used for the treatment of L-glutamic acid dysfunction related neural sick learn and the medicine of psychiatric disorders in purposes.
22. it is damaged that the purposes of claim 21, wherein said neurological and psychiatric disorders are selected from the brain that causes after heart bypass operation and the transplanting, apoplexy, cerebral ischemia, spinal cord injuries receptor, wound, perinatal hypoxia, heart stopping collecting, hypoglycemic neuronal damage, dull-witted, the dementia that AIDS brings out, presenile dementia, huntington's chorea, amyotrophic lateral sclerosis, ocular injury, retinopathy, cognitive disorder, spontaneous and drug-induced Parkinson's disease, muscle spasm and comprise with the muscle spasm diseases associated is trembled, epilepsy, faint from fear, the brain of epileptic state that is secondary to prolongation is damaged, migraine, the migraine headache, the urinary incontinence, the material tolerance, disease is given up in substance abuse, psychosis, schizophrenia, anxiety disorder, generalized anxiety disorder, paranoid fears, social phobia, obsession and post-traumatic stress disorder (PTSD), mood disorder, dysthymia disorders, mania, bipolar affective disorder, the circadian rhythm obstacle, jet lag, shift work syndrome, trigeminal neuralgia, hearing disability, tinnitus, the eyes macular degeneration, vomiting, cerebral edema, pain, acute pain, chronic pain, have an intense pain, refractory pain, neuropathic pain, pain after inflammatory pain and the wound, tardive dyskinesia, somnopathy, hypnolepsy, attention disappearance/hyperfunction obstacle and behavior disorder.
23. treat or prevent and need L-glutamic acid dysfunction related neural disease of the animal of treatment like this and the method for psychiatric disorders for one kind, this method comprises the step according to each compound among the claim 1-18 that gives described treatment of animals significant quantity.
24. treatment or prevention need that the L-glutamic acid dysfunction related neural of the animal of treatment like this is sick to be learned and the method for psychiatric disorders, this method comprises the step according to the medicinal compositions of claim 23 that gives described treatment of animals significant quantity.
25. according to the method for claim 23 or 24, it is damaged that wherein said neurological and psychiatric disorders are selected from the brain that causes after heart bypass operation and the transplanting, apoplexy, cerebral ischemia, spinal cord injuries receptor, wound, perinatal hypoxia, heart stopping collecting, hypoglycemic neuronal damage, dull-witted, the dementia that AIDS brings out, presenile dementia, huntington's chorea, amyotrophic lateral sclerosis, ocular injury, retinopathy, cognitive disorder, spontaneous and drug-induced Parkinson's disease, muscle spasm and comprise with the muscle spasm diseases associated is trembled, epilepsy, faint from fear, the brain of epileptic state that is secondary to prolongation is damaged, migraine, the migraine headache, the urinary incontinence, the material tolerance, disease is given up in substance abuse, psychosis, schizophrenia, anxiety disorder, generalized anxiety disorder, paranoid fears, social phobia, obsession and post-traumatic stress disorder (PTSD), mood disorder, dysthymia disorders, mania, bipolar affective disorder, the circadian rhythm obstacle, jet lag, shift work syndrome, trigeminal neuralgia, hearing disability, tinnitus, the eyes macular degeneration, vomiting, cerebral edema, pain, acute pain, chronic pain, have an intense pain, refractory pain, neuropathic pain, pain after inflammatory pain and the wound, tardive dyskinesia, somnopathy, hypnolepsy, attention disappearance/hyperfunction obstacle and behavior disorder.
26. the brain of epileptic state that the method for claim 25, neurological wherein and psychiatric disorders be selected from presenile dementia, be secondary to prolongation is damaged, disease, psychosis, schizophrenia, anxiety disorder, generalized anxiety disorder, paranoid fears, social phobia, obsession and post-traumatic stress disorder (PTSD), mood disorder, dysthymia disorders, mania and bipolar affective disorder are given up in material tolerance, substance abuse.
27. the method for a preparation formula Ic compound, this method comprises:
(a) at formula R1 (CR
8R
9)
nNH
2Existence under, make formula Ia compound:
Cyclisation is a formula Ib compound:
(b) make formula Ib compound and contain R
5The reagent cross-coupling, generate compound according to formula Ic:
Variable wherein as defined in claim 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2005/028760 WO2006020879A1 (en) | 2004-08-13 | 2005-08-12 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
| USPCT/US2005/028760 | 2005-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101277934A true CN101277934A (en) | 2008-10-01 |
Family
ID=36464390
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2006800353774A Pending CN101309905A (en) | 2005-08-12 | 2006-02-15 | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators |
| CNA2006800363117A Pending CN101277934A (en) | 2005-08-12 | 2006-02-15 | Metabotropic glutamate-receptor-potentiating isoindolones |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2006800353774A Pending CN101309905A (en) | 2005-08-12 | 2006-02-15 | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators |
Country Status (4)
| Country | Link |
|---|---|
| EP (2) | EP1912940A1 (en) |
| JP (2) | JP5031745B2 (en) |
| CN (2) | CN101309905A (en) |
| WO (2) | WO2007021309A1 (en) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7807706B2 (en) | 2005-08-12 | 2010-10-05 | Astrazeneca Ab | Metabotropic glutamate-receptor-potentiating isoindolones |
| TWI417095B (en) | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mglur2-receptors |
| US20080139846A1 (en) * | 2006-09-01 | 2008-06-12 | Astrazeneca Ab | New Process 298 |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| WO2008130853A1 (en) * | 2007-04-17 | 2008-10-30 | Astrazeneca Ab | Hydrazides and their use as metabotropic glutamate receptor potentiators - 681 |
| US20100197800A1 (en) * | 2007-04-23 | 2010-08-05 | Richard Friedman | Treatment and/or Prevention of Presbycusis by Modulation of Metabotropic Glutamate Receptor 7 |
| TWI443090B (en) | 2007-05-25 | 2014-07-01 | Abbvie Deutschland | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor) |
| TW200911255A (en) | 2007-06-07 | 2009-03-16 | Astrazeneca Ab | Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841 |
| TWI417100B (en) * | 2007-06-07 | 2013-12-01 | Astrazeneca Ab | Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators-842 |
| WO2009004430A1 (en) * | 2007-06-29 | 2009-01-08 | Pfizer Inc. | N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors |
| TW200927731A (en) | 2007-09-14 | 2009-07-01 | Ortho Mcneil Janssen Pharm | 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones |
| US9114138B2 (en) | 2007-09-14 | 2015-08-25 | Janssen Pharmaceuticals, Inc. | 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones |
| SA109300358B1 (en) | 2008-06-06 | 2012-11-03 | استرازينيكا ايه بي | Isoindolone Metabotropic Glutamate receptor Potentiators |
| GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
| TW201006801A (en) | 2008-07-18 | 2010-02-16 | Lilly Co Eli | Imidazole carboxamides |
| WO2010025890A1 (en) | 2008-09-02 | 2010-03-11 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
| AU2009304293B2 (en) | 2008-10-16 | 2012-04-26 | Addex Pharma S.A. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
| AU2009319387B2 (en) | 2008-11-28 | 2012-05-10 | Addex Pharma S.A. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
| CA2754688A1 (en) | 2009-03-11 | 2010-09-16 | Msd K.K. | Novel isoindolin-1-one derivative |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| CA2760259C (en) | 2009-05-12 | 2018-05-01 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| JP5634506B2 (en) | 2009-05-12 | 2014-12-03 | ジャンセン ファーマシューティカルズ， インコーポレイテッド | 1,2,3-Triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders |
| BR112012007737A2 (en) * | 2009-10-09 | 2015-09-15 | Celgene Corp | Processes for the preparation of 2- (1-phenylethyl) isoindolin-1-one compounds |
| WO2011051490A2 (en) | 2009-11-02 | 2011-05-05 | N.V. Organon | Heterocyclic derivatives |
| RU2012134329A (en) * | 2010-01-07 | 2014-02-20 | Астразенека Аб | METHOD FOR PRODUCING A POSITIVE ALLOSTERIC MODULATOR OF METABOTROPIC GLUTAMATE RECEPTORS-874 |
| US8314120B2 (en) | 2010-03-30 | 2012-11-20 | Abbott Gmbh & Co. Kg | Small molecule potentiators of metabotropic glutamate receptors |
| US8664214B2 (en) | 2010-03-30 | 2014-03-04 | AbbVie Deutschland GmbH & Co. KG | Small molecule potentiators of metabotropic glutamate receptors I |
| JP5852665B2 (en) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of the mGluR2 receptor |
| JP5852666B2 (en) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of the mGluR2 receptor |
| ES2552455T3 (en) | 2010-11-08 | 2015-11-30 | Janssen Pharmaceuticals, Inc. | 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
| AR088320A1 (en) | 2011-10-14 | 2014-05-28 | Incyte Corp | ISOINDOLINONE AND PIRROLOPIRIDINONE DERIVATIVES AS AKT INHIBITORS |
| HUE031313T2 (en) | 2011-10-28 | 2017-07-28 | Univ Vanderbilt | Substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
| JO3368B1 (en) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| JO3367B1 (en) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| LT3096790T (en) | 2014-01-21 | 2019-10-10 | Janssen Pharmaceutica, N.V. | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
| WO2015110435A1 (en) | 2014-01-21 | 2015-07-30 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
| TWI713455B (en) | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | Mnk inhibitors and methods related thereto |
| GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
| SG11201803234TA (en) | 2015-10-29 | 2018-05-30 | Effector Therapeutics Inc | Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit mnk1 and mnk2 |
| CN108602805A (en) | 2015-10-29 | 2018-09-28 | 效应治疗股份有限公司 | Isoindoline, azaisoindoline, indenone and the dihydro azepine indone inhibitor of MNK1 and MNK2 |
| WO2017087808A1 (en) | 2015-11-20 | 2017-05-26 | Effector Therapeutics, Inc. | Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers |
| CN105837557A (en) * | 2016-05-05 | 2016-08-10 | 青岛辰达生物科技有限公司 | Preparation method of alogliptin for treating type-II diabetes |
| CN106279182B (en) * | 2016-07-29 | 2019-06-07 | 中国药科大学 | A kind of pyrrolo- [2,1-a] iso-indole ketone compounds and its synthetic method |
| EP3582776B1 (en) | 2017-02-14 | 2023-11-08 | Effector Therapeutics, Inc. | Piperidine-substituted mnk inhibitors and methods related thereto |
| GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| EP3459939A1 (en) * | 2017-09-26 | 2019-03-27 | Pragma Therapeutics | Novel heterocyclic compounds as modulators of mglur7 |
| TW202035405A (en) | 2018-10-24 | 2020-10-01 | 美商伊凡克特治療公司 | Crystalline forms of mnk inhibitors |
| WO2020102216A1 (en) | 2018-11-13 | 2020-05-22 | Incyte Corporation | Substituted heterocyclic derivatives as pi3k inhibitors |
| US11161838B2 (en) | 2018-11-13 | 2021-11-02 | Incyte Corporation | Heterocyclic derivatives as PI3K inhibitors |
| WO2020102198A1 (en) | 2018-11-13 | 2020-05-22 | Incyte Corporation | Heterocyclic derivatives as pi3k inhibitors |
| CN110498759A (en) * | 2019-09-12 | 2019-11-26 | 天津瑞岭化工有限公司 | The synthetic method of isoindoline ketone compound |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE620654C (en) * | 1933-04-29 | 1935-10-24 | Smith & Sons Ltd S | Speed indicator |
| US3579524A (en) * | 1968-06-05 | 1971-05-18 | Miles Lab | 2-aminoalkyl derivatives of phthalimidines |
| US3993617A (en) * | 1975-10-30 | 1976-11-23 | Morton-Norwich Products, Inc. | Antifungal 2-substituted phthalimidines |
| DE3717561A1 (en) * | 1987-05-25 | 1988-12-08 | Thomae Gmbh Dr K | INDOL, ISOCHINOLINE AND BENZAZEPINE DERIVATIVES, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF |
| JPH02184667A (en) * | 1989-01-11 | 1990-07-19 | Meiji Seika Kaisha Ltd | N-n'-di-substituted piperazyl derivative and dysuria-improving agent containing the same |
| TW219935B (en) * | 1991-12-25 | 1994-02-01 | Mitsubishi Chemicals Co Ltd | |
| RU2124511C1 (en) * | 1993-05-14 | 1999-01-10 | Фармасьютикал Ко., Лтд | Piperazine derivatives |
| US5681954A (en) * | 1993-05-14 | 1997-10-28 | Daiichi Pharmaceutical Co., Ltd. | Piperazine derivatives |
| CN1158264C (en) * | 1997-11-21 | 2004-07-21 | Nps药物有限公司 | Metabotropic glutamate receptor antagonists for treating central nervous system disease |
| KR100815772B1 (en) * | 2000-02-29 | 2008-03-20 | 미쯔비시 웰 파마 가부시키가이샤 | Novel cyclic amide derivatives |
| DE10031391A1 (en) * | 2000-07-03 | 2002-02-07 | Knoll Ag | Bicyclic compounds and their use for the prophylaxis and therapy of cerebral ischemia |
| ES2291329T3 (en) * | 2000-07-18 | 2008-03-01 | Dainippon Sumitomo Pharma Co., Ltd. | INHIBITORS OF SEROTONINE RECAPTATION. |
| DE10238865A1 (en) * | 2002-08-24 | 2004-03-11 | Boehringer Ingelheim International Gmbh | New carboxamides are melanin-concentrating hormone receptor antagonists, useful for treating e.g. metabolic diseases, diabetes, eating disorders, cardiovascular disease, emotional disorders, reproductive and memory disorders |
| GB0223232D0 (en) * | 2002-10-07 | 2002-11-13 | Pfizer Ltd | Chemical compounds |
| US20070135485A1 (en) * | 2003-10-22 | 2007-06-14 | Gillig James R | Novel mch receptor antagonists |
| WO2005074643A2 (en) * | 2004-01-30 | 2005-08-18 | Smithkline Beecham Corporation | Benzamide compounds useful as rock inhibitors |
| AU2005219791B2 (en) * | 2004-03-05 | 2011-06-09 | Msd K.K. | Diaryl-substituted five-membered heterocycle derivative |
| EA014881B1 (en) * | 2004-03-05 | 2011-02-28 | Ниссан Кемикал Индастриз, Лтд. | Substitited alkylbenzene derivatives |
| TW200613272A (en) * | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
-
2006
- 2006-02-15 EP EP06720759A patent/EP1912940A1/en not_active Withdrawn
- 2006-02-15 JP JP2008525976A patent/JP5031745B2/en not_active Expired - Fee Related
- 2006-02-15 JP JP2008525977A patent/JP2009509921A/en active Pending
- 2006-02-15 CN CNA2006800353774A patent/CN101309905A/en active Pending
- 2006-02-15 WO PCT/US2006/005247 patent/WO2007021309A1/en active Application Filing
- 2006-02-15 WO PCT/US2006/005246 patent/WO2007021308A1/en active Application Filing
- 2006-02-15 EP EP06720758A patent/EP1912939A1/en not_active Withdrawn
- 2006-02-15 CN CNA2006800363117A patent/CN101277934A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1912940A1 (en) | 2008-04-23 |
| CN101309905A (en) | 2008-11-19 |
| JP2009509920A (en) | 2009-03-12 |
| WO2007021308A1 (en) | 2007-02-22 |
| WO2007021309A1 (en) | 2007-02-22 |
| JP2009509921A (en) | 2009-03-12 |
| JP5031745B2 (en) | 2012-09-26 |
| EP1912939A1 (en) | 2008-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101277934A (en) | Metabotropic glutamate-receptor-potentiating isoindolones | |
| CN101679403B (en) | Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators 842 | |
| US8153638B2 (en) | Metabotropic glutamate-receptor-potentiating isoindolones | |
| CN101193869B (en) | Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | |
| CN101679402A (en) | Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators 841 | |
| US5990126A (en) | Quinolinic sulfide derivatives acting as NMDA receptor antagonists and process for preparation thereof | |
| CN101511802A (en) | Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | |
| JP4898783B2 (en) | 1H-Quinazoline-2,4-diones and their use as AMPA receptor ligands | |
| US20090149505A1 (en) | Metabotropic Glutamate Receptor-Potentiating Isoindolones | |
| WO2008130853A1 (en) | Hydrazides and their use as metabotropic glutamate receptor potentiators - 681 | |
| TW200836743A (en) | Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions | |
| CN101426773A (en) | 5-phenyl-3-benzyl-oxazolidin-2-one derivatives and related compounds as metabotropic glutamate receptor potentiators for the treatment of neurological and psychiatric disorders | |
| CN101124207A (en) | Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | |
| CN102015715A (en) | Fused pyrimidineone compounds as TRPV3 modulators | |
| JP2013500267A (en) | Substituted benzimidazole sulfonamides and substituted indole sulfonamides as mGLuR4 enhancers | |
| JP2007530694A (en) | Biaryl-substituted pyrazinones as sodium channel blockers | |
| JP2013540794A (en) | Alpha-7 nicotinic receptor modulator for the treatment of pain, psychotic disorders, cognitive disorders or Alzheimer's disease | |
| TW201307284A (en) | FAAH inhibitors | |
| KR20110020797A (en) | Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators | |
| CN1218464A (en) | 2,3 disulbstituted-4 (3H)-quinazolinones | |
| CN101675034A (en) | Pyridione derivatives as P38A MAPK inhibitor | |
| CN101356160A (en) | Trisubstituted quinazolinone derivatives as vanilloid antagonists | |
| CN103237794A (en) | P2X4 receptor antagonist | |
| CN104995182A (en) | Substituted quinoxaline derivatives and their use as positive allosteric modulators of mglur4 | |
| CN104955826A (en) | Spiro-quinazolinone derivatives useful for the treatment of neurological diseases and conditions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20081001 |